CA2256133A1 - Drinking fluid - Google Patents
Drinking fluid Download PDFInfo
- Publication number
- CA2256133A1 CA2256133A1 CA002256133A CA2256133A CA2256133A1 CA 2256133 A1 CA2256133 A1 CA 2256133A1 CA 002256133 A CA002256133 A CA 002256133A CA 2256133 A CA2256133 A CA 2256133A CA 2256133 A1 CA2256133 A1 CA 2256133A1
- Authority
- CA
- Canada
- Prior art keywords
- amount
- vitamin
- concentration
- drinking fluid
- fluid according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000035622 drinking Effects 0.000 title claims abstract description 64
- 239000012530 fluid Substances 0.000 title claims abstract description 64
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 55
- 239000011707 mineral Substances 0.000 claims abstract description 55
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940088594 vitamin Drugs 0.000 claims abstract description 32
- 229930003231 vitamin Natural products 0.000 claims abstract description 32
- 235000013343 vitamin Nutrition 0.000 claims abstract description 32
- 239000011782 vitamin Substances 0.000 claims abstract description 32
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 18
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 18
- 239000011718 vitamin C Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 229940046009 vitamin E Drugs 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011701 zinc Substances 0.000 claims abstract description 15
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 15
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000003651 drinking water Substances 0.000 claims abstract description 10
- 235000020188 drinking water Nutrition 0.000 claims abstract description 10
- 229960003495 thiamine Drugs 0.000 claims abstract description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract 2
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract 2
- 239000011691 vitamin B1 Substances 0.000 claims abstract 2
- 235000010755 mineral Nutrition 0.000 claims description 52
- 239000000126 substance Substances 0.000 claims description 32
- 229940024606 amino acid Drugs 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 235000018102 proteins Nutrition 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 239000011573 trace mineral Substances 0.000 claims description 16
- 235000013619 trace mineral Nutrition 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 12
- 229910052698 phosphorus Inorganic materials 0.000 claims description 12
- 239000011574 phosphorus Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 10
- 229960004203 carnitine Drugs 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 235000019155 vitamin A Nutrition 0.000 claims description 9
- 239000011719 vitamin A Substances 0.000 claims description 9
- 229940045997 vitamin a Drugs 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims description 7
- 235000013734 beta-carotene Nutrition 0.000 claims description 7
- 239000011648 beta-carotene Substances 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229960000367 inositol Drugs 0.000 claims description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- 235000018192 pine bark supplement Nutrition 0.000 claims description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims description 7
- 239000011716 vitamin B2 Substances 0.000 claims description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims description 7
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 6
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 6
- 229960002747 betacarotene Drugs 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052748 manganese Inorganic materials 0.000 claims description 6
- 239000011572 manganese Substances 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 229930003537 Vitamin B3 Natural products 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052785 arsenic Inorganic materials 0.000 claims description 5
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 229910052750 molybdenum Inorganic materials 0.000 claims description 5
- 239000011733 molybdenum Substances 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 5
- 229960005190 phenylalanine Drugs 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 229910052720 vanadium Inorganic materials 0.000 claims description 5
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 5
- 235000019160 vitamin B3 Nutrition 0.000 claims description 5
- 239000011708 vitamin B3 Substances 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 239000006035 Tryptophane Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 229910052796 boron Inorganic materials 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 150000002215 flavonoids Chemical class 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 235000008729 phenylalanine Nutrition 0.000 claims description 4
- 235000021317 phosphate Nutrition 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- 238000000053 physical method Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 229960004295 valine Drugs 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229930003571 Vitamin B5 Natural products 0.000 claims description 3
- 239000004411 aluminium Substances 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 235000009492 vitamin B5 Nutrition 0.000 claims description 3
- 239000011675 vitamin B5 Substances 0.000 claims description 3
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 19
- 230000007812 deficiency Effects 0.000 description 16
- 230000004060 metabolic process Effects 0.000 description 15
- 229960005069 calcium Drugs 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000011942 biocatalyst Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 6
- 229930003316 Vitamin D Natural products 0.000 description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 229920002770 condensed tannin Polymers 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 229940106796 pycnogenol Drugs 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000022558 protein metabolic process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-SSDOTTSWSA-N 3-[[(2s)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoic acid Chemical compound OCC(C)(C)[C@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-SSDOTTSWSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920000877 Melamine resin Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 101150114843 Mgll gene Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000005428 Thiamine Deficiency Diseases 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047612 Vitamin B2 deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940025974 arginine 25 mg Drugs 0.000 description 1
- 201000007590 ariboflavinosis Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000021158 dinner Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000001909 effect on DNA Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 229940064302 folacin Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000000909 keratomalacia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-N laevulinic acid Natural products CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940096435 niacin 25 mg Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000004223 riboflavin deficiency Diseases 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940033158 vitamin b6 1 mg Drugs 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/54—Mixing with gases
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/30—Treatment of water, waste water, or sewage by irradiation
- C02F1/32—Treatment of water, waste water, or sewage by irradiation with ultraviolet light
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Hydrology & Water Resources (AREA)
- Medicinal Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Inorganic Chemistry (AREA)
- Environmental & Geological Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Lubricants (AREA)
Abstract
The invention relates to a drinking fluid, comprising water freed of inorganic and organic minerals and preferably degased. In this drinking water at least one organic mineral and at least three different vitamins are dissolved. As an organic mineral it contains zinc in an amount between 5 mg/l and 25 mg/l, preferably 5 mg/l to 15 mg/l and as vitamins at least vitamin C in an amount from 20 µg/l to 5 g/l, preferably 30 µg/l to 5 g/l, vitamin E in an amount from 0.8 µg/l to 27 µg/l, preferably 0.87 µg/l to 25 µg/l and vitamin B1 in an amount from 0.6 mg/l to 1.7 g/l, preferably 0.7 mg/l to 1.5 g/l.
Description
CA 022~6133 1998-12-1~
DRINKING FLUID
BACKGROUND OF THE INVENTION
Field of the Invention The invention relates to a drinking fluid, comprising water liberated of inorganic and organic mineral substances and preferably degased, characterised in that at least one organic mineral and at least three different vitamins are dissolved therein, whereby zinc is contained as an organic mineral in an amount between 5 mg/l and 25 mg/l, preferably 5 mg/l to 15 mg/l and as vitamin.~ at least vitamin C in an amount 20 ~lg/l to 5 g/l, preferably 30 ~lg/l to S g/l, vitamin E in an amount from 0.8 ~lg/l to 27 llg/l, preferably 0.87 ,ug/l to 25 llg/l and vitamin Bl in an amount 0.6 mg/l to 1.7 g/l, preferably 0.7 mg/l to 1.5 g/l.
and a method for producing said drinking fluid.
Description of the Prior Art It is already known from DE 32 01 405 C2 to create a sodium and potassium free, mineralised drinking water formulation, which comprises an aqueous solution of distilled water in which four mineral substances in the form of strontium, magnesium, calcium and lithium are dissolved. By means of this composition of the drinking water formulation the growth of diseased coronary vessels should be reduced. The disadvantage is that the drinking water solution ~. ~ _ CA 022~6133 1998-12-1~
. .
is only suitable for a single specific use and the intake of active ingredients is low because of the inorganic nature of the salts in the body.
Drinking water found today in our environment is contaminated by nitrates, pesticides, halogen compounds etc. and this cont~mination cannot be corrected by waterworks or not to an adequate degree. Many bottled waters are also heavily contaminated as they are collected from springs.
SUMMARY OF THE INVENTION
The objective of the present invention is to create a drinking fluid, in which the supply of active or mineral substances to the body of a human being is possible by the amount of liquid consumed daily, in order thus to achieve and maintain a desirable state of health.
This objective is achieved in that at least one organic mineral and at least three different vitamins are dissolved therein, whereby zinc is contained as an organic mineral in an amount between 5 mg/l and 25 mg/l, preferably 5 mg/l to 15 mg/l and as vit~minc at least vitamin C in an amount 20 llg/l to 5 g/l, preferably 30 ,ug/l to 5 g/l, vitamin E in an amount from 0.8 ~lg/l to 27 ,ug/l, preferably 0.87 ,ug/l to 25 llg/l and vitamin Bl in an amount 0.6 mg/l to 1.7 g/l, preferably 0.7 mg/l to 1.5 g/l. An advantage is that mineral substances are CA 02256133 1998-12-1~
mainly supplied in the form of organic salts - in particular the cations necessary for the organism - so that bioavailability compared to ordinary mineral waters, in which minerals are present in an inorganic form, can be increased. A further advantage is that the supply of active or mineral ingredients is in liquid form, which is why extra casing material, as used in ordinary capsules, can be dispensed with. In addition, the inconvenient handling of combinations of active ingredients pressed into tablet form, which in some cases only dissolve very slowly in water, is avoided.
A further advantage is that an overdosage of active ingredients is not possible or only with difficulty, as this would require the intake of a considerable amount of the drinking fluid.
A development of the drinking fluid which contains vitamin A in an amount between 120 ,ug /1 and 190 mg/l, preferably 125 ~lg/l to 188 mg/l and/or vitamin B6 in an amount between 0.8 mg/l and 270 mg/l, preferably 1 mg/l to 250 mg/l and/or vitamin B2 in an amount between 0.5 mg/l to 120 mg/l, preferably 0.8 mg/l to 100 mg/l is also advantageous, as hereby the energy and protein metabolism, the nitrogen metabolism and powers of vision are positively influenced.
In the embodiment that contains as organic minerals calcium in an amount between 5 mg/l and 650 mg/l, preferably 25 mg/l to 400 mg/l and .
CA 022~6133 1998-12-1~
magnesium in an amount between 3.5 mg/l and 250 mg/l, preferably 3.8 mg/l to 150 mg/l and folic acid in an amount between 40 llg/l to 220 ,ug/l, preferably S0 ~ug/l to 200 llg/L it is an advantage that the formation of bones and teeth, the function of the heart circulatory systems and the maturation of red blood cells are supported.
By means of the embodiment of the drinking fluid that contains choline in a concentration between 30 ~lg /1 and 1.8 g/l, preferably 35 ~lg /1 to l.S g/l and/or as an organic mineral selenium in an amount between 13 llg/l and 250 llg/l, preferably lS llg /1 to 125 llg /1 and/or vitamin Bs in an amount between 2.5 mg/l to 0.7 g/l, preferably 3 mg/l to 0.5 g/l and/or beta carotene in an amount from 30 llg /1 to 0.90 mg/l, preferably 31 llg /1 to 0.75 mg/l and/or cysteine in an amount from 20 mg/l to 1.6 g/l, preferably 25 mg/l to l.S g/l, biochemical processes, for example methylations, the negative effects of peroxides formed from fatty acids, the metabolism of the cells and blood viscosity can be influenced.
The embodiments of the drinking fluid that contains the vitamin Bl2 in an amount from 13 llg /1 to 8 mg/l, preferably 15 ~Lg /1 to 5 mg/l and/or D in an amount from 1.3 llg /1 to 5 mg/l, preferably 1.5 llg /1 to 2.5 mg/l and/or biotin in an amount from 40 llg /1 to 0.18 mg/l, preferably 50 ~Lg /l to O.lS mg/l and/or the vitamin B3 in a concentration of between 7 mg/l and 120 mg/l, preferably 9 mg/l to 100 mg/l and/or lysine and/or proline respectively in a concentration of .
CA 022~6133 1998-12-1~
,._ between 70 mg/l to 260 mg/l, preferably 80 mg/l to 250 mg/l, have an advantageous effect on DNA synthesis, the calcium or phosphorus balance, amino acid or fatty acid metabolism, the working of the heart muscle cells and the protection of the artery wall.
A further development of the drinking fluid in which carnitine is present in a concentration of between 20 mg/l and 280 mg/l, preferably 25 mg/l to 175 mg/l and/or arginine in a concentration of between 25 mg/l and 85 mg/l, preferably 27 mg/l to 82 mg/l and/or coenzyme Q10 in a concentration of between 3 mg/l and 58 mg/l, preferably 5 mg/l to 30 mg/l, is also advantageous, as hereby stress to the vessel walls can be reduced and the production and provision of energy improved.
By means of the embodiments of the drinking fluid, which as organic salts contains potassium and/or sodium in a concentration of 10 mg/l to 70 mg/l respectively, preferably 15 mg/l to 45 mg/l and/or phosphorus, for example as phosphate, in a concentration of between 2 mg/l and 550 mg/l, preferably 3 mg/l to 400 mg/l, and/or as organic minerals it contains manganese in a concentration of between 0.6 mg/l and 3.4 mg/l, preferably 0.75 mg/l to 3 mg/l and/or chromium in a concentration of between 6 ~lg/l and 0.12 mg/l, preferably between 7.5 ~lg/l and 0.1 mg/l and/or molybdenum in concentration of between 2.5 llg /1 and 70 mg/l, preferably 3 llg/l to 5 mg/l, it is possible to make ....... ..
CA 022~6133 1998-12-1~
., ,~
available a sufficient amount of the mineral substances necessary for body reactions.
An embodiment of the drinking fluid, which contains inositol in a concentration of between 10 mg/l and 80 mg/l, preferably 15 mg/l to 75 mg/l and/or pycogenol in a concentration of between 4 mg/l and 18 mg/l, preferably 5 mg/l to 15 mg/l and/or as an organic mineral copper in a concentration of between 200 mg/l to 1200 mg/l, preferably 250 mg/l to 1000 mg/l, is also advantageous, as hereby catalytic metabolic functions are supported.
An embodiment of the drinking fluid, which contains iron in an amount between 0.5 mg/l to 14 mg/l, preferably 0.65 mg/l to 7 mg/l and/or iodine in an amount between 20 ~g /1 and 150 ~lg /1, preferably 25 ~g /1 to 75 ,ug /1, and/or flavonoids in an amount between 20 mgll and 40 mg/l, preferably 25 mg/l, and/or vitamin K in an amount between 30 llg/l and 70 ~lg/l, preferably 50 llg/l, is also advantageous, as hereby blood clotting, haemoglobin formation and energy control mechanisms are positively influenced.
In the developments of the drinking fluid, which contains isoleucine in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 300 mg/l and/or leucine in an amount from 1 mg/l to 1500 mg/l, preferably 11 mg/l to 300 mg/l and/or methionine in an amount from 1 mg/l to 1500 mg/l, preferably 14 mg/l to 300 mg/l, and/or phenyl-alanine in an amount from 1 mg/l to 1500 mg/l, preferably 13 mg/l to 300 mg/l and/or CA 022~6133 1998-12-1~
threonine in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 200 mg/l and/or tryptophane in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 200 mg/l and/or valine in an amount from 1 mg/l to 1500 mg/l, preferably 11 mg/l to 300 mg/l, and/or asparagine in an amount from 1 ~lg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or serine in an amount from 1 llg/l to 10 g/1, preferably 100 mg/l to 16.00 mg/l and/or glutamic acid in an amount from 1 llg /l to 10 g/l, preferably 100 mg/l to 1600 mg/l, and/or glycine in an amount from 1 ~g /l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or alanine in an amount from 1 llg /l to 10 g/1, preferably 100 mg/l to 1600 mg/l and/or tyrosine in an amount from 1 llg /l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or histidine in an amount from 1 ~g /l to 10 g/l, preferably 100 mg/l to 1600 mg/l, it is an advantage that important essential amino acids can be supplied to the body by the necessary dai!y intake of liquid. Thus in a simple manner a basic supply of the building blocks necessary for making for example hormones is possible. Examples are the hormones insulin and its antagonist glucagon produced in the islets of Langerhans. In addition, methionine is considered as a main source of sulphur for the human body and plays an important role in the transfer of methyl groups in protein biosynthesis and in detoxification processes. Glutamic acid however is a component of muscle protein and is of central importance in the whole amino acid metabolism, in that it acts as an amino group donor. Glycine plays an important role in haem biosynthesis via the ~-amino laevulinic acid and functions in inhibiting neurotransmitters. Tyrosine plays an important role in the melamine balance and is necessary for the production of adrenaline and CA 022~6133 1998-12-1~
.,,~
thyroid hormones. At the melanosomes of the melanocytes it is converted into two forms of melamine. If this metabolism is disturbed it causes an oversensitivity of the skin or eyes to light. Leucine is needed by the organism mainly for the production of serum albumins and serum globulins, isoleucine for the production of haemoglobin and serum proteins. Phenylalanine is the precursor of tyrosine, tyrosine is necessary for the hydrolysis of peptide bonds.
Tryptophane is for the production of serotonin and melatonin, valine is in general irreplaceable in the making of protein. Asparagine is required in protein biosynthesis, alanine for the enzymatic metabolic processes of sugars and acids.
Histidine is used for the synthesis of haemoglobin and in many enzyme proteins.
The embodiments of the drinking fluid, which contains as minerals chloride in an amount from 1 mg/l to lO0 mg/l, preferably 1 mg/l to 20 mg/l and/or fluoride in an amount from 0.5 llg/l to 1.5 ~lg/l, preferably 0.5 ~lg/l to 1 ,ug/l, and/or as organic minerals boron in an amount from 0.01 llg/l to 300 llg/l and/or alllminium in an amount from 0.01 llg/l to 50 ~g/l, and/or arsenic in an amount from 0.01 ~g /l to 10 ~g /l, preferably 0.01 ~g /l to 2 llg /1 and/or lithium in an amount from 1 ,ug /l to 200 mg/l, preferably 1 ~Lg/1 to 100 mg/l and/or vanadium in an amount from 1 llg/l to 5 mg/l, are also advantageous in that the human or in certain cases the animal body can be supplied with important minerals. Thus the supply of fluoride positively influences the CA 022~6133 1998-12-1~
formation of bones and teeth or acts as a caries prophylactic. Lithium can be considered a prophylactic means for manic depressive states.
Arsenic, lithium and vanadium are essential trace elements. Arsenic is important for the whole protein metabolism, especially in the thyroid, lithium also encourages the elimination of uric acid. Vanadium is required by the metabolism, in adenosine triphosphatases, phosphatases and other enzymes of the energy metabolism. Boron and aluminium are elements which occur in very small amounts in the organism, and therefore should be supplemented in cases of deficiency.
The objective of the invention is however also achieved by removing all inorganic and organic minerals and preferably any dissolved from drinking water, whereupon vitamins and/or proteins and/or amino acids and/or minerals and/or trace elements are added to this pure water according to one or more of the preceding claims, and the thus obtained product is preferably treated to a final sterilisation by e.g. UV light radiation. Here in an advantageous manner an optimal water quality is ensured, in that the water is freed in one or more stages of all substances, and in one procedure the necessary available substances are added. The possible uses of such a drinking fluid are very wide ranging, but the main use is for daily consumption. The drinking fluid is also particularly suitable for special uses, e.g. various therapeutic and/or medicinal indications, in which the purified water acts as a carrier medium for the necessary substances.
CA 022~6133 1998-12-1~
An embodiment, in which the concentration of the substances added to the water at most reaches the saturation concentration of the individual components depending on the combination of substances, is also advantageous according to which the formation of a precipitate in the drinking fluid and thus possible associated transportation problems on the production of the drinking fluid can be avoided.
The advantageous embodiment, in which to remove dissolved CO2 and for the homogenous distribution of the measured substances preferably nitrogen or compressed air is blown in, makes it possible on the one hand to avoid a peraciding of the drinking fluid and on the other hand to homogenise the metered active ingredients easily.
An advantage of the embodiment, where the product properties are changed by physical methods, preferably by energising and/or changing the molecular structure, is that the excellent properties of the product can be increased further by additional means, such as energising.
Lastly it is an advantage, to dissolve CO2 in the drinking fluid, preferably in a concentration which is above the maximum saturation concentration, and/or to add CO2 after dissolving all of the added vitamins, amino acids, proteins, minerals and trace elements. In this way a drinking fluid ... . . ..
CA 022~6133 1998-12-1~
,._ can be produced, which depending on the taste requirements of the user of the drinking fluid produces a greater or lesser bubbling sensation on drinking.
The invention is explained in more detail in the following description.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
First of all it should be noted that because of the large number of possible active and mineral substances only individual combinations of examples can be described. Also individual characteristics of the combinations of characteristics shown in the individual embodiments can also form individual solutions according to the invention.
Owing to the large number of possible active and mineral substances and the large number of combinations of substances formed therefrom for a drinking fluid according to the invention in Table 1 below all possible addable substances such as vitamins, proteins, amino acids, minerals and trace elements are listed.
Table 1: Substances that can be added Vitamins:
Vitamin A 120 ~g/l to 190 mg/l preferably 125 llg/l to 188 mg/l Vitamin D 1.3 ~Lg/l to S mg/l preferably 1.5 llg/l to 2.5 mg/l CA 022~6133 1998-12-1~
Vitamin E 0.8 llg/l to 27 ,ug/l preferably 0.87 ~g/l to 25 ~lg/l Vitamin K 30 ,ug/l to 70 ~lg/l preferably 50 llg/l Vitamin Bl 0.6 mg/l to 1.7 g/l preferably 0.7 mg/l to 1.5 g/l Vitamin B2 0.5 mg/l to 120 mg/l preferably 0.8 mg/l to 100 mg/l Vitamin B3 7 mg/l to 120 mg/l preferably 9 mg/l to 100 mg/l Vitamin B5 2.5 mg/l to 0.7 g/l preferably 3 mg/l to 0.5 g/l Vitamin B6 0.8 mg/l to 270 mg/l preferably 1 mg/l to 250 mg/l Vitamin Bl2 13 llg/l to 8 mg/l preferably 15 llg/l to 5 mg/l Vitamin C 20 llg/l to 5 g/l preferably 30 ~lg/l to 5 g/l Flavonoids 20 mg/l to 40 mg/l preferably 25 mg/l Folic acid 40 ~g/l to 220 ,ug/l preferably 50 ,ug/l to 200 ~g/l Beta carotene 30 ~lg/l to 0.9 mg/l preferably 31 ~lg/l to 0.75 mg/l Proteins and amino acids:
Coenzyme Q-10 3 mg/l to 58 mg/l preferably 5 mg/l to 30 mg/l Inositol 10 mg/l to 80 mg/l preferably 15 mg/l to 75 mg/l Isoleucine 1 mg/l to 1000 mg/l preferably 10 mg/l to 300 mg/l Leucine 1 mg/l to 1500 mg/l preferably 11 mg/l to 300 mg/l Lysine 70 mg/l to 260 mg/l preferably 80 mg/l to 250 mg/l Methionine 1 mg/l to 1500 mg/l preferably 14 mg/l to 300 mg/l Phenylalanine 1 mg/l to 1500 mg/l preferably 13 mg/l to 300 mg/l Threonine 1 mg/l to 1000 mg/l preferably 10 mg/l to 200 mg/l Trypthophane l mg/l to 1000 mg/l preferably 10 mg/l to 200 mg/l CA 022~6133 1998-12-1~
Choline 30 ~lg/l to 1.8 g/l preferably 35 ~lg/l to 1.5 g/l Biotin 40 ~lg/l to 0.18 mg/l preferably 50 ~g/l to 0.15 mg/l Valine l mg/l to 1500 mg/l preferably 11 mg/l to 300 mg/l Pycnogenol 4 mg/l to 18 mg/l preferably 5 mg/l to 15 mg/l Carnitine 20 mg/l to 280 mg/l preferably 25 mg/l to 175 mg/l Cysteine 20 mg/l to 1.6 g/l preferably 25 mg/l to 1.5 g/l Asparagine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Serine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Glutamic acid 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Proline 70 mg/l to 260 mg/l preferably 80 mg/l to 250 mg/l Glycine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Alanine 1 ~g/l to 10 g/l preferably 100 mg/l to 1600 mg/l Tyrosine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Histidine 1 ~lg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Arginine 25 mg/l to 85 mg/l preferably 27 mg/l to 82 mg/l Minerals and trace elements:
Sodium lO mg/l to 70 mg/l preferably 15 mg/l to 45 mg/l Potassium 10 mg/l to 70 mg/l preferably 15 mg/l to 45 mg/l Magnesium 3.5 mg/l to 250 mg/l preferably 3.8 mg/l to 150 mg/l Calcium 5 mg/l to 650 mg/l preferably 25 mg/l to 400 mg/l Iron 0.5 mg/l to 14 mg/l preferably 0.65 mg/l to 7 mg/l CA 022~6133 1998-12-1 Zinc 5 mg/l to 25 mg/l preferably 5 mg/l to 15 mg/l Manganese 0.6 mg/l to 3.4 mg/l preferably 0.75 mg/l to 3 mg/l Copper 200mg/lto 1200mg/1 preferably 250 mg/l to 1000 mg/l Phosphorus 2 mg/l to 550 mg/l preferably 3 mg/l to 400 mg/l Selenium 13 ~lg/l to 250 llg/l preferably 15 llg/l to 125 ~g/l Chloride 1 mg/l to 100 mg/l preferably 1 mg/l to 20 mg/l Boron 0.01 ~lg/l to 300 ,ug/l Fluoride 0.5 ~lg/l to 1.5 llg/l preferably 0.5 llg/l to 1 ~g/l Aluminium 0.01 llg/l to 50 llg/l Lithium O.Ol llg/lto 200mg/1 preferably 1 llg/l to 100 mg/l Iodide 20 ,ug/l to 150 llg/l preferably 25 ~Lg/l to 75 llg/l Arsenic 0.01 ,ug/l to 10 ~lg/l preferably 0.01 llg/l to 2 ,ug/l Vanadium 1 ~lg/l to 5 mg/l Molybdenum 2.5 ~lg/l to 70 mg/l preferably 3 llg/1 to 5 mg/l Chromium 6 llg/l to 0.12 mg/l preferably 7.5 llg/l to 0.1 mg/l Mineral substances and trace elements are preferably used in the form of organic salts. Therefore, it is possible for example to use salts of carbohydrates such as gluconate or also salts of lactic acid such as e.g. calcium lactate or salts of acetic acid such as e.g. alkali or alkaline earth acetates for the composition of the drinking water formulation. Phosphorus can be used in the form of organic phosphates. Of course it is also possible to provide the mineral substances and trace elements in the form of inorganic salts. This is mainly an CA 022~6133 1998-12-1~
_ advantage for the addition of the listed anions required by the organism, such as e.g. chloride, fluoride.
The human body's requirement for protein is about 0.34 g/kg body weight per day. This basic requirement can be covered advantageously by drinking the drinking fluid according to the invention, which is provided with proteins.
The daily requirement of sulphur, mainly in the form of sulphides is 0.7 mg/kg body weight and can for example be covered by taking amino acids such as methionine.
It is of course also possible with the drinking fluid according to the invention also to improve the wellbeing of animals, for example pets. A
corresponding adjustment of the amounts of active substances used can be made according to the individual species.
The production of a drinking fluid according to the invention can be performed in general so that all inorganic and organic minerals and preferably gases dissolved therein are removed from the drinking water. To this purified clean water the required active ingredients such as vit~mins, proteins, amino acids, minerals and trace elements are added and the resulting obtained product is subjected to a final sterilisation, for example by UV light radiation.
CA 02256l33 l998-l2-l~
Preferably, the concentration of the substances added to the water should reach at most the saturation concentration of the individual components de~ending on the combinations of substances.
To remove dissolved CO2 or to homogenise the thus added active substances, preferably a gaseous medium such as nitrogen or compressed air can be blown through the drinking fluid according to the invention.
For the further activation of the drinking fluid according to the invention it is also possible to change the properties of the product by physical methods, for example by energising, changing the molecular structure or the like.
Of course, for drinking fluids according to the invention it is also possible, preferably after the dissolution of all added substances to add C O2 deliberately, preferably in a concentration above the maximum saturation concentration, so that the end consumer of the drinking fluid can be given a special, bubbly and refreshing taste experience.
ExamDle 1 Drinkinp fluid for oDtimal heart circulation Contents:
vitgm;n~:
CA 022~6133 1998-12-1~
Vitamin C 450 mg/l to 1500 mg/l Vitamin E 2.5 llg/l to 7.5 ~g/l Beta carotene 31.25 llg/l to 100 ~lg/l Vitamin Bl 5 mg/l to 20 mg/l Vitamin B2 5 mg/l to 20 mg/l Vitamin B3 32.5 mg/l to 100 mg/l Vitamin B5 30 mg/l to 100 mg/1 Vitamin B6 7.5 mg/l to 25 mg/l Vitamin Bl2 15 llg/l to 50 llg/l Vitamin D 2.5 llg/l to 7.5 ~lg/l Folic acid 65 ,ug/l to 200 ~g/l Biotin 0.05 mg/l to 0.15 mg/l Minerals:
Calcium 25 mg/l to 75 mg/1 Magnesium 30 mg/l to 100 mg/1 Potassium 15 mg/l to 45 mg/l Phosphorus 10 mg/l to 30 mg/l Trace elements:
Zinc 5 mg/l to 15 mg/1 Manganese 1 mg/l to 3 mg/l Copper 250 mg/l to 1000 mg/l . , CA 022~6133 1998-12-1~
Selenium 15 llg/l to 50 ~g/l Chromium 7.5 ,ug/l to 25 ~g/l Molybdenum 3 ~g/l to 10 ~Lg/l Amino acids and other important cell factors:
Lysine 80 mg/l to 250 mg/l Proline 80 mg/l to 250 mg/l Carnitine 25 mg/l to 75 mg/l Arginine 27.5 mg/l to 82.5 mg/l Cysteine 25 mg/l to 75 mg/l Coenzyme Q- 10 5 mg/l to 15 mg/l Pycnogenol 5 mg/l to 15 mg/l To produce this drinking fluid for supplying the circulation of the heart drinking water can be used as a base, which is purified by suitable methods, e.g.
pressure filtration through a semipermeable membrane or distillation. After sterilisation by e.g. UV light radiation the active ingredients are added, whereby it should be ensured that minerals and trace elements are added in the form of organic salts. In this way for example calcium can be used in the form of lactate, magnesium and potassium as gluconate, manganese and zinc as acetate. Any CO2 still dissolved in the water which has the property on ultra filtration through the filter membrane of diffusing, can be removed by blowing in nitrogen or compressed air for example, and at the said time the added salts CA 022~6133 1998-12-1~
,.._ can be distributed homogeneously. Further positive properties can be given to the product, if the latter for example is energised by means of apparatus functioning according to physical methods or other types of molecular structural changes can be made. For the highest requirements it is also possible to subject the product to a second sterilisation by UV light radiation for example.
The sum of the individual properties of the added vitamins, minerals, trace elements, amino acids and other important cell factors acts positively on the human organism. Thus e.g. vitamin C is vital for the stability of the blood vessels, the heart muscle tissue and other body organs and is also an important wound healing means in our body and responsible for the repair of blood vessel walls. It is the most important antioxidant in our body and an important biocatalyst for many metabolic steps, such as for example the breakdown of cholesterol. In addition, vitamin C is an irreplaceable bioenergy donor of the cell metabolism for the most important energy carrier molecules in ADH, ADP-H and in FAD-H.
Vitamin E (tocopherol) is one of the most important fat soluble antioxidants in the body. It mainly protects the membranes (outer skin) of millions of body cells including the cells of the heart and the artery walls from oxidation damage. In addition, it contributes to the reduced adhesiveness of the blood platelets and advantageous flowing properties of the blood.
I
CA 022~6133 1998-12-1 Beta carotene (provitamin A) is also an additional important fat-soluble antioxidant and contributes to optimum blood viscosity and to a reduced risk of clotting.
Vitamin Bl (thiamine) is a cofactor for pyrophosphate, one of the most important biocatalysts of the metabolism and contributes to the optimum cell energy balance of the heart circulatory system and other organs.
Vitamin B2 (riboflavin) is a structural feature of the FAD energy transport molecule in all cells.
Vitamin B3 (nicotinic acid) is a component of the structure of the energy transport molecule NAD or related energy carriers and thereby partly responsible for supplying energy to the body. By means of the added vitamin C
these used energy carriers are recharged with biological energy. It is particularly important as because of the high work output of the heart muscle cells an optimal supply of these cell fuels is necessary for the heart circulatory system.
Vitamin Bs (pantothenic acid) is a structural component of the acetyl coenzyme -A- molecule, of the central metabolic molecule of each cell of our body. Vitamin Bs is essential in order to prevent backflows in the cell metabolism, as the metabolic paths oi carbohydrates, proteins and fats inside the cells cross one another at this molecule.
- CA 022~6133 1998-12-1~
-Vitamin B6 (pyridoxal phosphate) as a structural component of the pyridoxal phosphate molecule is an important biocalatyst in the metabolism of amino acids and proteins in body cells, essential for the production of red blood cells, which transport oxygen to the cells of the heart circulatory system and other organs.
Vitamin Bl2 (cobalamin) is also necessary for the production of red blood cells. It is also essential for the effective metabolism of proteins and certain fatty acids. A severe Bl2 deficiency results in pernicious anaemia a severe form of anaemia.
Folic acid is also crucial for the transport of oxygen.
The last three vitamins are a good example of the way vitamins work together. It is also important to know which of these natural substances the body needs in what amount.
Biotin is an important biocatalyst for the metabolism of carbohydrates, fats and proteins.
Likewise inositol is a biocatcalyst, responsible for the sugar, fat and protein metabolism. Inositol is also a component of the biological information exchange and assists with the processing of biological information in the cell, . ~ -- CA 022~6133 1998-12-1~
.__ such as e.g. the biological information contained in the hormones. The importance of inositol for the heart circulatory system is quickly evident, as hormones such as adrenaline, insulin and others play an important role in the regulation of the heart function.
As already known from several clinical investigations, the minerals like the vitamins play an important role in the human organism. In particular, the cations are vital components of biocatalysts which are essential in a plurality of metabolic steps. A deficiency or an excess of minerals results in certain cases in life-threatening conditions like a deficiency or an excess of vitamins. Calcium, magnesium and potassium are among the most important minerals.
Calcium has numerous functions in the heart circulatory system. It contributes to muscle contractability and is also responsible for the myocardial transfer. Calcium is important in order to ensure an optimum function of the nerve impulses responsible for a regular heart beat.
Magnesium, the natural calcium antagonist, was able in clinical studies to reduce high blood pressure. It can also contribute to the normalisation of a regular heart beat and plays a role in muscle contraction.
Potassium plays a particularly important role in muscle activity and in nerve transfer. It is also important like calcium to ensure an optimal function of the nerve impulses including the stimulation system of the heart.
, ~ .. . . ..
CA 022~6133 1998-12-1~
. _ Trace elements are essential biocatalysts, which are imperative for a large number of cell metabolic stages. They are only required by the body in very small amounts as already expressed by the term "trace element". A lack of these elements however results in deficiency symptoms. For example with a selenium deficiency cardio myopathy can be observed in Keshan disease.
Amino acids are important building blocks of proteins, which as enzymes of important biocatalysts, as hormones for metabolism regulation or as structural proteins, components of biomembranes or as transport proteins, are responsible for the transport of vital substances, such as e.g. oxygen by haemoglobin. Most amino acids in our body come from proteins which we take in through food. Amino acids which our body can make itself are termed "non essential". Amino acids that the body cannot produce itself and therefore have to be supplied through food are termed "essential" amino acids.
Lysine is an essential amino acid and an important component of collagen and stability molecules. Said amino acid is a significant factor in preventing deposits on the artery wall. In addition, it is a parent substance for the body's own production of earnitine.
Proline is an important building block of collagen molecules and contributes like lysine to the proteetion of the artery wall. Proline can unlike CA 022~6133 1998-12-1 lysine be made by the body itself, the amount of proline produced however is often too low, so that it seem sensible to compensate the requirement by food.
Arginine is the parent substance of vessel wall factors, which leads to a reduced stress of the vessel walls and thereby contributes to a normalisation of high blood pressure. Arginine reduces the adhesiveness of the blood platelets and contributes to an improvement of the flow properties of the blood.
Cysteine is an important parent substance for the production of glutathione an important "body's own" antioxidant. Glutathione together with other antioxidants is responsible for the protection of body tissue from free radicals.
Carnitine can be made in the body itself as a non-essential amino acid.
However, the body's own production is too low as for proline. An optimal supply of carnitine is essential in order to ensure an effective fat metabolism, in particular of triglycerides. In addition, it is an important carrier molecule, which transports fatty acids to extract energy into the biological power houses of the cells (mitochondria). It also ensures the optimal function of the heart muscle cells, which because of their continual work have a high turnover of carnitine. As shown in clinical studies carnitine significantly improves the pumping power of the heart in patients with heart deficiencies. In addition, it is known that carnitine in patients with irregular heart beats (arrhythmia) contributes to a normalisation of the heart rhythm. In both cases carnitine CA 022~6133 1998-12-1 brings about an optimising of the cell energy and thereby an improved performance of millions of heart muscle cells.
Coenzyme Q-10 is also known as ubiquinone and plays an excellent role as a catalyst of the biological respiratory chain in the energy centre of the cells.
It is particularly important for the provision of biological energy in the muscle cells including the heart muscle tissue, which because of the its output has a high turnover of coenzyme Q-10. Here too clinical studies have shown that coenzyme Q-10 in patients with weak hearts can improve the pumping function of the heart.
Pycnogenol comprises a groups of bioflavonoids, which are important as catalysts for various metabolic functions. In particular pycnogenol improves the stabilising effect of vitamin C on the binding tissue of the body including the blood vessel walls and pycnogenol also acts as an antioxidant.
F,x~nple 2 Water for increa~in~ intelli~ence Contents:
Flavonoids 25 mg/l Biotin 50 ~g/l Choline 35 mg/l CA 022~6133 1998-12-1~
._ Folic acid 50 llg/l Inositol 15 mg/l Niacin 25 mg/l Pantothenic acid 25 mg/l Vitamin B6 6 mg/l Vitamin Bl 1.85 mg/l Riboflavin 2.5 mg/l Vitamin A 187.5 mg/l Vitamin Bl2 5 mg/l Vitamin C 50 mg/l Vitamin D 1.5 ~lg/l Vitamin E 0.88 ~lg/l Vitamin K 50 llg/l Calcium 50 mg/l Chromium 0.1 mg/l Magnesium 3.8 mg/l Manganese 0.75 mg/l Molybdenum 0.05 mg/l Iodine 25 llg/l Iron 0. 65 mg/l Zinc 5 mg/l CA 022~6133 1998-12-1~
The production of this drinking fluid can be performed in the same way as the methods described in Example 1.
The advantage of this drinking fluid is that non-verbal intelligence, i.e.
intelligence that is not influenced by schooling or the like can be increased by 10 ~b in a period of up to 8 months. This was proved in an experiment on English school children, who received a combination, which according to German and Austrian guidelines would be available only on prescription and would be inadmissible anyway in its variety. From preliminary investigations it emerged that the children eat a combination of foods (school dinners), which was common practice. If it is taken into consideration that the time period was comparatively short and the organs of children were in very good health, it is understandable why the director of the experiment was surprised by the result.
The conclusion can be drawn from this result that the children against all expectations were malnourished. The suspicion that this is true for the whole population seems justified. The above combination of micronutirents and macronutirents takes into account this fact. With this drinking fluid without additional measures being necessary such as for example the daily intake of tablets or capsules, the intelligence and as a result the productivity of the population can be increased in a simple manner.
F,x~mple 3 -' CA 02256133 1998-12-1~
Water ~in~t the causes of oxidative stress Contents:
Selenium 125 mg/l Vitamin A 125 ~g/l to 250 ,ug/l Vitamin E 12.5 ~g/l to 25 ~g/l Zinc 25 mg/l Vitamin B2 50 mg/l to 100 mg/l Vitamin C 1.5 g/l to 5 g/l Cysteine O.S g/l to 1.5 g/l Vitamin Bl 150 mg/l to 1.5 g/l Vitamin Bs 125 mg/l to 500 mg/l Vitamin B6 125 mg/l to 250 mg/l Choline 0.5 g/l to 1.5 g/l Beta carotene 125 llg/l to 750 llg/l In addition to inadequate nutrition and environmental influences also a large number of medicines increase a radical-forming oxidation process. It has previously not been possible to even halfway copy the immune system of the body, which in normal conditions operates highly effectively. Antibiotics against infections and chemotherapies against cancer never reach the potency of the oxygen. There are and remain substances foreign to the body (xenobiotics) and thus there is an incomplete replacement of natural immunity. They do not CA 022~6133 1998-12-1~
._ differentiate between friend and foe and thus also damage healthy structures.
The doctor thus achieves a main effect at the cost of many side effects.
Medicines can thus worsen the courses of illnesses. The aim of any therapy should be to balance out the redox potential to the value 0. As according to Hypocrates health is the best means against illness a precautionary measure is also to interrupt a possibly already long continuing oxidative stress so that the body can regain its self-regulating abilities. It is possible in many cases, by taking antioxidants or highly dosed nutrients to improve chronic damage, such as e.g. allergies or even remove them altogether. In any case conventional medical therapies should be accompanied to a much greater extent than before by supplements.
In the case of private precautions the emphasis is not on the complete avoidance of illnesses but on a better immunity against unavoidable attacks on health. This is achieved by drinking this water daily.
Example 4 Drinkin~ fluid to cover the daily requirement of vitamins. proteins, amino acids. minerals and trace elements.
Composition:
- -r~
CA 022~6133 1998-12-1 Vitamin A 400 mg/l Vitamin D 2.5 mg/l Vitamin E 5 ~g/l Vitamin C 30 ~g/l Vitamin Bl 0.7 mg/l Vitamin B2 0.8 mg/l Niacin 9 mg/l Vitamin B6 1 mg/l Biotin 75 llg/l Vitamin Bl2 0-5 ~g/l Folacin 100 llg/l Pantothenic acid 3 mg/l Caicium 400 mg/l Phosphorus 400 mg/l Iron 7 mg/l Magnesium 150 mg/l Zinc 7.5 mg/l Iodine 75 )lg/l Effect: Vitamin A supports vision. In addition, the normal structure of the epithelial tissue is dependent on vitamin A. Vitamin A also ensures the stability of the lysosomes and contributes to glycoprotein synthesis. A
. . . . I
CA 022~6133 1998-12-1~
-deficiency causes night blindness, perifollicular hyperkeratosis, xerophthalmy, keratomalacia and increased morbidity and mortality in childhood.
Vitamin E is an intracellular antioxidant and catcher of free radicals in biological membranes. An absence or excess in the body leads to neurological disturbances and zeroid deposits in the muscle.
Vitamin Bl is a coenzyme for the decarboxylation of a-keto acids and the transketolase reaction. A known syndrome with thiamine deficiency is beriberi with peripheral neurological, cerebral and cardiovascular deficiency symptoms. A primary thi~mine deficiency occurs as a result of insufficient intake, especially in the case of exclusive nutrition with machine shelled and polished rice. A secondary thi~mine deficiency occurs with increased need, e.g.
pregnancy, breastfeeding, feverish illnesses and with thyroid hyperactivity with restricted absorption, e.g. prolonged diarrhoea, with restricted utilisation, e.g.
severe liver damage.
Riboflavin (vitamin B2) functions both as a flavin mononucleotide and flavin adenine dinucleotide, as an essential coenzyme in many redox reactions in the carbohydrate metabolism. It is involved in the make up and in the maintenance of mucous membranes. Riboflavin deficiency results in damage to the mouth area, the eyes, the skin and the genital region.
CA 022~6133 1998-12-1~
_ Vitamin C is essential for the formation of collagen and obtains the substances of mesenchymatose origin ~binding tissue, osteoid substance of the bone, dentine of the teeth). It promotes the healing of wounds and the recovery of burns. As a strong reducing agent it can reversibly transfer hydrogen or electrons. Thus it forms in its reduced form, dehydroascorbic acid, a cellular redox system. Vitamin C is involved in the phenylalanine and tyrosine metabolism and activates as a reducing agent the enzymes, which hydroxylise the proline and the lysine of the protocollagen after translation to hydroxyproline and hydroxylysine. Vitamin C also causes folic acid which is coupled with components of nutrients to be released from these conjugations and supports in addition the resorption of iron.
Vitamin B6 is involved in the metabolism of nitrogen e.g. on the transamination of the porphyrine and haem synthesis, the tryptophane conversion to niacin and the linoleic acid metabolism. Deficiencies relate to the metabolism of blood, the skin and the central nervous system.
Vitamin D is important for the resorption of calcium and phosphorus, for the resorption, mineralisation and collagen maturation of bone and for the tubular reresorption of phosphorus. A known bone disease which is caused by vitamin D deficiency is known in children as rickets and in adults as osteomalacia CA 022~6133 1998-12-1~
~ ,._ Vitamin Bl2 contributes to the maturation of red blood cells, neural functions, DNA synthesis in connection with the folic acid coenzymes and to methionine and acetate synthesis.
In addition to the daily supply of corresponding doses of vitamins, as already described above, the daily intake of minerals is particularly important.
For example, calcium and phosphorus are particularly important for the formation of bones and teeth. Phosphorus contributes in addition to energy storage in the form of phosphates, especially adenosine triphosphate, which on consuming energy is reduced to adenosine diphosphate. A deficiency of phosphorus also causes weakness, disruption to the blood cells and irritability.
Iron in turn contributes considerably to the oxygen supply of the human body. It is complexly bonded in haemoglobin, especially in red blood pigment haem and performs the transport of oxygen from the lungs into the cells or removes the products of combustion in particular CO2 from the cells into the lungs. A very low level of iron results in reduced performance or learning difficulties and anaemia.
F,Y~Inple S
Drinkinp fluid for supplyin~ prepn~nt and breastfeedinP mothers Contents:
CA 022~6133 1998-12-1~
Vitamin C 35 mg/l to 47 mg/l Vitamin E S ~g/l to 6 ~Lg/l Vitamin B~ 0.6 mg/l to 0.8 mg/l Zinc 8 mg/l to 9.5 mg/l The adequate nutrition of pregnant or breastfeeding mothers and consequently of the unborn or new born child is of particular importance for maintaining health. A drinking fluid with the above contents can contribute in an advantageous manner to covering the increased need for vit~minc and minerals.
A primary vitamin E deficiency often results in premature babies, in particular if the amount of unsaturated fatty acids in the baby's food is very high. Protein calorie undernourished children often have a low vitamin E serum deficiency. A low vitamin E serum level and haemolysis increased by antioxidation products in premature babies who are fed with foods containing vegetable oil, are found in connection with oedemas and flaky dermatitis. In adults a deficiency in vitamin E results in a reduced lifetime of red blood cells.
Said deficiencies can be avoided by the daily intake of vitamin E.
The effects of vitamin C and vitamin Bl and the effects of a deficiency of these vitamins has already been discussed in the above examples.
. .
CA 022~6133 1998-12-1~
,_ An adequate supply of zinc is particularly important as the zinc content of the body is between 1 g and 2.5 g, whereby the greatest amount is in bones, teeth, hair, skin liver and muscles. The complexing of the zinc supplied with food by means of eating only fibre and phylate rich bread, geophagy and a parasite attack can lead to a reduced resorption and thereby to deficiencies. As known from clinical studies children who have too little zinc in the body show a lack of appetite, are too small and have a reduced sense of taste. A zinc deficiency in the mother can cause anencephaly in children.
Finally, it should be noted that the described drinking fluid with its special combinations of active ingredients are only examples of the solution according to the invention. Individual components of the drinking fluid and different combinations of characteristics to the above examples can form independent solutions according to the invention.
DRINKING FLUID
BACKGROUND OF THE INVENTION
Field of the Invention The invention relates to a drinking fluid, comprising water liberated of inorganic and organic mineral substances and preferably degased, characterised in that at least one organic mineral and at least three different vitamins are dissolved therein, whereby zinc is contained as an organic mineral in an amount between 5 mg/l and 25 mg/l, preferably 5 mg/l to 15 mg/l and as vitamin.~ at least vitamin C in an amount 20 ~lg/l to 5 g/l, preferably 30 ~lg/l to S g/l, vitamin E in an amount from 0.8 ~lg/l to 27 llg/l, preferably 0.87 ,ug/l to 25 llg/l and vitamin Bl in an amount 0.6 mg/l to 1.7 g/l, preferably 0.7 mg/l to 1.5 g/l.
and a method for producing said drinking fluid.
Description of the Prior Art It is already known from DE 32 01 405 C2 to create a sodium and potassium free, mineralised drinking water formulation, which comprises an aqueous solution of distilled water in which four mineral substances in the form of strontium, magnesium, calcium and lithium are dissolved. By means of this composition of the drinking water formulation the growth of diseased coronary vessels should be reduced. The disadvantage is that the drinking water solution ~. ~ _ CA 022~6133 1998-12-1~
. .
is only suitable for a single specific use and the intake of active ingredients is low because of the inorganic nature of the salts in the body.
Drinking water found today in our environment is contaminated by nitrates, pesticides, halogen compounds etc. and this cont~mination cannot be corrected by waterworks or not to an adequate degree. Many bottled waters are also heavily contaminated as they are collected from springs.
SUMMARY OF THE INVENTION
The objective of the present invention is to create a drinking fluid, in which the supply of active or mineral substances to the body of a human being is possible by the amount of liquid consumed daily, in order thus to achieve and maintain a desirable state of health.
This objective is achieved in that at least one organic mineral and at least three different vitamins are dissolved therein, whereby zinc is contained as an organic mineral in an amount between 5 mg/l and 25 mg/l, preferably 5 mg/l to 15 mg/l and as vit~minc at least vitamin C in an amount 20 llg/l to 5 g/l, preferably 30 ,ug/l to 5 g/l, vitamin E in an amount from 0.8 ~lg/l to 27 ,ug/l, preferably 0.87 ,ug/l to 25 llg/l and vitamin Bl in an amount 0.6 mg/l to 1.7 g/l, preferably 0.7 mg/l to 1.5 g/l. An advantage is that mineral substances are CA 02256133 1998-12-1~
mainly supplied in the form of organic salts - in particular the cations necessary for the organism - so that bioavailability compared to ordinary mineral waters, in which minerals are present in an inorganic form, can be increased. A further advantage is that the supply of active or mineral ingredients is in liquid form, which is why extra casing material, as used in ordinary capsules, can be dispensed with. In addition, the inconvenient handling of combinations of active ingredients pressed into tablet form, which in some cases only dissolve very slowly in water, is avoided.
A further advantage is that an overdosage of active ingredients is not possible or only with difficulty, as this would require the intake of a considerable amount of the drinking fluid.
A development of the drinking fluid which contains vitamin A in an amount between 120 ,ug /1 and 190 mg/l, preferably 125 ~lg/l to 188 mg/l and/or vitamin B6 in an amount between 0.8 mg/l and 270 mg/l, preferably 1 mg/l to 250 mg/l and/or vitamin B2 in an amount between 0.5 mg/l to 120 mg/l, preferably 0.8 mg/l to 100 mg/l is also advantageous, as hereby the energy and protein metabolism, the nitrogen metabolism and powers of vision are positively influenced.
In the embodiment that contains as organic minerals calcium in an amount between 5 mg/l and 650 mg/l, preferably 25 mg/l to 400 mg/l and .
CA 022~6133 1998-12-1~
magnesium in an amount between 3.5 mg/l and 250 mg/l, preferably 3.8 mg/l to 150 mg/l and folic acid in an amount between 40 llg/l to 220 ,ug/l, preferably S0 ~ug/l to 200 llg/L it is an advantage that the formation of bones and teeth, the function of the heart circulatory systems and the maturation of red blood cells are supported.
By means of the embodiment of the drinking fluid that contains choline in a concentration between 30 ~lg /1 and 1.8 g/l, preferably 35 ~lg /1 to l.S g/l and/or as an organic mineral selenium in an amount between 13 llg/l and 250 llg/l, preferably lS llg /1 to 125 llg /1 and/or vitamin Bs in an amount between 2.5 mg/l to 0.7 g/l, preferably 3 mg/l to 0.5 g/l and/or beta carotene in an amount from 30 llg /1 to 0.90 mg/l, preferably 31 llg /1 to 0.75 mg/l and/or cysteine in an amount from 20 mg/l to 1.6 g/l, preferably 25 mg/l to l.S g/l, biochemical processes, for example methylations, the negative effects of peroxides formed from fatty acids, the metabolism of the cells and blood viscosity can be influenced.
The embodiments of the drinking fluid that contains the vitamin Bl2 in an amount from 13 llg /1 to 8 mg/l, preferably 15 ~Lg /1 to 5 mg/l and/or D in an amount from 1.3 llg /1 to 5 mg/l, preferably 1.5 llg /1 to 2.5 mg/l and/or biotin in an amount from 40 llg /1 to 0.18 mg/l, preferably 50 ~Lg /l to O.lS mg/l and/or the vitamin B3 in a concentration of between 7 mg/l and 120 mg/l, preferably 9 mg/l to 100 mg/l and/or lysine and/or proline respectively in a concentration of .
CA 022~6133 1998-12-1~
,._ between 70 mg/l to 260 mg/l, preferably 80 mg/l to 250 mg/l, have an advantageous effect on DNA synthesis, the calcium or phosphorus balance, amino acid or fatty acid metabolism, the working of the heart muscle cells and the protection of the artery wall.
A further development of the drinking fluid in which carnitine is present in a concentration of between 20 mg/l and 280 mg/l, preferably 25 mg/l to 175 mg/l and/or arginine in a concentration of between 25 mg/l and 85 mg/l, preferably 27 mg/l to 82 mg/l and/or coenzyme Q10 in a concentration of between 3 mg/l and 58 mg/l, preferably 5 mg/l to 30 mg/l, is also advantageous, as hereby stress to the vessel walls can be reduced and the production and provision of energy improved.
By means of the embodiments of the drinking fluid, which as organic salts contains potassium and/or sodium in a concentration of 10 mg/l to 70 mg/l respectively, preferably 15 mg/l to 45 mg/l and/or phosphorus, for example as phosphate, in a concentration of between 2 mg/l and 550 mg/l, preferably 3 mg/l to 400 mg/l, and/or as organic minerals it contains manganese in a concentration of between 0.6 mg/l and 3.4 mg/l, preferably 0.75 mg/l to 3 mg/l and/or chromium in a concentration of between 6 ~lg/l and 0.12 mg/l, preferably between 7.5 ~lg/l and 0.1 mg/l and/or molybdenum in concentration of between 2.5 llg /1 and 70 mg/l, preferably 3 llg/l to 5 mg/l, it is possible to make ....... ..
CA 022~6133 1998-12-1~
., ,~
available a sufficient amount of the mineral substances necessary for body reactions.
An embodiment of the drinking fluid, which contains inositol in a concentration of between 10 mg/l and 80 mg/l, preferably 15 mg/l to 75 mg/l and/or pycogenol in a concentration of between 4 mg/l and 18 mg/l, preferably 5 mg/l to 15 mg/l and/or as an organic mineral copper in a concentration of between 200 mg/l to 1200 mg/l, preferably 250 mg/l to 1000 mg/l, is also advantageous, as hereby catalytic metabolic functions are supported.
An embodiment of the drinking fluid, which contains iron in an amount between 0.5 mg/l to 14 mg/l, preferably 0.65 mg/l to 7 mg/l and/or iodine in an amount between 20 ~g /1 and 150 ~lg /1, preferably 25 ~g /1 to 75 ,ug /1, and/or flavonoids in an amount between 20 mgll and 40 mg/l, preferably 25 mg/l, and/or vitamin K in an amount between 30 llg/l and 70 ~lg/l, preferably 50 llg/l, is also advantageous, as hereby blood clotting, haemoglobin formation and energy control mechanisms are positively influenced.
In the developments of the drinking fluid, which contains isoleucine in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 300 mg/l and/or leucine in an amount from 1 mg/l to 1500 mg/l, preferably 11 mg/l to 300 mg/l and/or methionine in an amount from 1 mg/l to 1500 mg/l, preferably 14 mg/l to 300 mg/l, and/or phenyl-alanine in an amount from 1 mg/l to 1500 mg/l, preferably 13 mg/l to 300 mg/l and/or CA 022~6133 1998-12-1~
threonine in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 200 mg/l and/or tryptophane in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 200 mg/l and/or valine in an amount from 1 mg/l to 1500 mg/l, preferably 11 mg/l to 300 mg/l, and/or asparagine in an amount from 1 ~lg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or serine in an amount from 1 llg/l to 10 g/1, preferably 100 mg/l to 16.00 mg/l and/or glutamic acid in an amount from 1 llg /l to 10 g/l, preferably 100 mg/l to 1600 mg/l, and/or glycine in an amount from 1 ~g /l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or alanine in an amount from 1 llg /l to 10 g/1, preferably 100 mg/l to 1600 mg/l and/or tyrosine in an amount from 1 llg /l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or histidine in an amount from 1 ~g /l to 10 g/l, preferably 100 mg/l to 1600 mg/l, it is an advantage that important essential amino acids can be supplied to the body by the necessary dai!y intake of liquid. Thus in a simple manner a basic supply of the building blocks necessary for making for example hormones is possible. Examples are the hormones insulin and its antagonist glucagon produced in the islets of Langerhans. In addition, methionine is considered as a main source of sulphur for the human body and plays an important role in the transfer of methyl groups in protein biosynthesis and in detoxification processes. Glutamic acid however is a component of muscle protein and is of central importance in the whole amino acid metabolism, in that it acts as an amino group donor. Glycine plays an important role in haem biosynthesis via the ~-amino laevulinic acid and functions in inhibiting neurotransmitters. Tyrosine plays an important role in the melamine balance and is necessary for the production of adrenaline and CA 022~6133 1998-12-1~
.,,~
thyroid hormones. At the melanosomes of the melanocytes it is converted into two forms of melamine. If this metabolism is disturbed it causes an oversensitivity of the skin or eyes to light. Leucine is needed by the organism mainly for the production of serum albumins and serum globulins, isoleucine for the production of haemoglobin and serum proteins. Phenylalanine is the precursor of tyrosine, tyrosine is necessary for the hydrolysis of peptide bonds.
Tryptophane is for the production of serotonin and melatonin, valine is in general irreplaceable in the making of protein. Asparagine is required in protein biosynthesis, alanine for the enzymatic metabolic processes of sugars and acids.
Histidine is used for the synthesis of haemoglobin and in many enzyme proteins.
The embodiments of the drinking fluid, which contains as minerals chloride in an amount from 1 mg/l to lO0 mg/l, preferably 1 mg/l to 20 mg/l and/or fluoride in an amount from 0.5 llg/l to 1.5 ~lg/l, preferably 0.5 ~lg/l to 1 ,ug/l, and/or as organic minerals boron in an amount from 0.01 llg/l to 300 llg/l and/or alllminium in an amount from 0.01 llg/l to 50 ~g/l, and/or arsenic in an amount from 0.01 ~g /l to 10 ~g /l, preferably 0.01 ~g /l to 2 llg /1 and/or lithium in an amount from 1 ,ug /l to 200 mg/l, preferably 1 ~Lg/1 to 100 mg/l and/or vanadium in an amount from 1 llg/l to 5 mg/l, are also advantageous in that the human or in certain cases the animal body can be supplied with important minerals. Thus the supply of fluoride positively influences the CA 022~6133 1998-12-1~
formation of bones and teeth or acts as a caries prophylactic. Lithium can be considered a prophylactic means for manic depressive states.
Arsenic, lithium and vanadium are essential trace elements. Arsenic is important for the whole protein metabolism, especially in the thyroid, lithium also encourages the elimination of uric acid. Vanadium is required by the metabolism, in adenosine triphosphatases, phosphatases and other enzymes of the energy metabolism. Boron and aluminium are elements which occur in very small amounts in the organism, and therefore should be supplemented in cases of deficiency.
The objective of the invention is however also achieved by removing all inorganic and organic minerals and preferably any dissolved from drinking water, whereupon vitamins and/or proteins and/or amino acids and/or minerals and/or trace elements are added to this pure water according to one or more of the preceding claims, and the thus obtained product is preferably treated to a final sterilisation by e.g. UV light radiation. Here in an advantageous manner an optimal water quality is ensured, in that the water is freed in one or more stages of all substances, and in one procedure the necessary available substances are added. The possible uses of such a drinking fluid are very wide ranging, but the main use is for daily consumption. The drinking fluid is also particularly suitable for special uses, e.g. various therapeutic and/or medicinal indications, in which the purified water acts as a carrier medium for the necessary substances.
CA 022~6133 1998-12-1~
An embodiment, in which the concentration of the substances added to the water at most reaches the saturation concentration of the individual components depending on the combination of substances, is also advantageous according to which the formation of a precipitate in the drinking fluid and thus possible associated transportation problems on the production of the drinking fluid can be avoided.
The advantageous embodiment, in which to remove dissolved CO2 and for the homogenous distribution of the measured substances preferably nitrogen or compressed air is blown in, makes it possible on the one hand to avoid a peraciding of the drinking fluid and on the other hand to homogenise the metered active ingredients easily.
An advantage of the embodiment, where the product properties are changed by physical methods, preferably by energising and/or changing the molecular structure, is that the excellent properties of the product can be increased further by additional means, such as energising.
Lastly it is an advantage, to dissolve CO2 in the drinking fluid, preferably in a concentration which is above the maximum saturation concentration, and/or to add CO2 after dissolving all of the added vitamins, amino acids, proteins, minerals and trace elements. In this way a drinking fluid ... . . ..
CA 022~6133 1998-12-1~
,._ can be produced, which depending on the taste requirements of the user of the drinking fluid produces a greater or lesser bubbling sensation on drinking.
The invention is explained in more detail in the following description.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
First of all it should be noted that because of the large number of possible active and mineral substances only individual combinations of examples can be described. Also individual characteristics of the combinations of characteristics shown in the individual embodiments can also form individual solutions according to the invention.
Owing to the large number of possible active and mineral substances and the large number of combinations of substances formed therefrom for a drinking fluid according to the invention in Table 1 below all possible addable substances such as vitamins, proteins, amino acids, minerals and trace elements are listed.
Table 1: Substances that can be added Vitamins:
Vitamin A 120 ~g/l to 190 mg/l preferably 125 llg/l to 188 mg/l Vitamin D 1.3 ~Lg/l to S mg/l preferably 1.5 llg/l to 2.5 mg/l CA 022~6133 1998-12-1~
Vitamin E 0.8 llg/l to 27 ,ug/l preferably 0.87 ~g/l to 25 ~lg/l Vitamin K 30 ,ug/l to 70 ~lg/l preferably 50 llg/l Vitamin Bl 0.6 mg/l to 1.7 g/l preferably 0.7 mg/l to 1.5 g/l Vitamin B2 0.5 mg/l to 120 mg/l preferably 0.8 mg/l to 100 mg/l Vitamin B3 7 mg/l to 120 mg/l preferably 9 mg/l to 100 mg/l Vitamin B5 2.5 mg/l to 0.7 g/l preferably 3 mg/l to 0.5 g/l Vitamin B6 0.8 mg/l to 270 mg/l preferably 1 mg/l to 250 mg/l Vitamin Bl2 13 llg/l to 8 mg/l preferably 15 llg/l to 5 mg/l Vitamin C 20 llg/l to 5 g/l preferably 30 ~lg/l to 5 g/l Flavonoids 20 mg/l to 40 mg/l preferably 25 mg/l Folic acid 40 ~g/l to 220 ,ug/l preferably 50 ,ug/l to 200 ~g/l Beta carotene 30 ~lg/l to 0.9 mg/l preferably 31 ~lg/l to 0.75 mg/l Proteins and amino acids:
Coenzyme Q-10 3 mg/l to 58 mg/l preferably 5 mg/l to 30 mg/l Inositol 10 mg/l to 80 mg/l preferably 15 mg/l to 75 mg/l Isoleucine 1 mg/l to 1000 mg/l preferably 10 mg/l to 300 mg/l Leucine 1 mg/l to 1500 mg/l preferably 11 mg/l to 300 mg/l Lysine 70 mg/l to 260 mg/l preferably 80 mg/l to 250 mg/l Methionine 1 mg/l to 1500 mg/l preferably 14 mg/l to 300 mg/l Phenylalanine 1 mg/l to 1500 mg/l preferably 13 mg/l to 300 mg/l Threonine 1 mg/l to 1000 mg/l preferably 10 mg/l to 200 mg/l Trypthophane l mg/l to 1000 mg/l preferably 10 mg/l to 200 mg/l CA 022~6133 1998-12-1~
Choline 30 ~lg/l to 1.8 g/l preferably 35 ~lg/l to 1.5 g/l Biotin 40 ~lg/l to 0.18 mg/l preferably 50 ~g/l to 0.15 mg/l Valine l mg/l to 1500 mg/l preferably 11 mg/l to 300 mg/l Pycnogenol 4 mg/l to 18 mg/l preferably 5 mg/l to 15 mg/l Carnitine 20 mg/l to 280 mg/l preferably 25 mg/l to 175 mg/l Cysteine 20 mg/l to 1.6 g/l preferably 25 mg/l to 1.5 g/l Asparagine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Serine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Glutamic acid 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Proline 70 mg/l to 260 mg/l preferably 80 mg/l to 250 mg/l Glycine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Alanine 1 ~g/l to 10 g/l preferably 100 mg/l to 1600 mg/l Tyrosine 1 llg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Histidine 1 ~lg/l to 10 g/l preferably 100 mg/l to 1600 mg/l Arginine 25 mg/l to 85 mg/l preferably 27 mg/l to 82 mg/l Minerals and trace elements:
Sodium lO mg/l to 70 mg/l preferably 15 mg/l to 45 mg/l Potassium 10 mg/l to 70 mg/l preferably 15 mg/l to 45 mg/l Magnesium 3.5 mg/l to 250 mg/l preferably 3.8 mg/l to 150 mg/l Calcium 5 mg/l to 650 mg/l preferably 25 mg/l to 400 mg/l Iron 0.5 mg/l to 14 mg/l preferably 0.65 mg/l to 7 mg/l CA 022~6133 1998-12-1 Zinc 5 mg/l to 25 mg/l preferably 5 mg/l to 15 mg/l Manganese 0.6 mg/l to 3.4 mg/l preferably 0.75 mg/l to 3 mg/l Copper 200mg/lto 1200mg/1 preferably 250 mg/l to 1000 mg/l Phosphorus 2 mg/l to 550 mg/l preferably 3 mg/l to 400 mg/l Selenium 13 ~lg/l to 250 llg/l preferably 15 llg/l to 125 ~g/l Chloride 1 mg/l to 100 mg/l preferably 1 mg/l to 20 mg/l Boron 0.01 ~lg/l to 300 ,ug/l Fluoride 0.5 ~lg/l to 1.5 llg/l preferably 0.5 llg/l to 1 ~g/l Aluminium 0.01 llg/l to 50 llg/l Lithium O.Ol llg/lto 200mg/1 preferably 1 llg/l to 100 mg/l Iodide 20 ,ug/l to 150 llg/l preferably 25 ~Lg/l to 75 llg/l Arsenic 0.01 ,ug/l to 10 ~lg/l preferably 0.01 llg/l to 2 ,ug/l Vanadium 1 ~lg/l to 5 mg/l Molybdenum 2.5 ~lg/l to 70 mg/l preferably 3 llg/1 to 5 mg/l Chromium 6 llg/l to 0.12 mg/l preferably 7.5 llg/l to 0.1 mg/l Mineral substances and trace elements are preferably used in the form of organic salts. Therefore, it is possible for example to use salts of carbohydrates such as gluconate or also salts of lactic acid such as e.g. calcium lactate or salts of acetic acid such as e.g. alkali or alkaline earth acetates for the composition of the drinking water formulation. Phosphorus can be used in the form of organic phosphates. Of course it is also possible to provide the mineral substances and trace elements in the form of inorganic salts. This is mainly an CA 022~6133 1998-12-1~
_ advantage for the addition of the listed anions required by the organism, such as e.g. chloride, fluoride.
The human body's requirement for protein is about 0.34 g/kg body weight per day. This basic requirement can be covered advantageously by drinking the drinking fluid according to the invention, which is provided with proteins.
The daily requirement of sulphur, mainly in the form of sulphides is 0.7 mg/kg body weight and can for example be covered by taking amino acids such as methionine.
It is of course also possible with the drinking fluid according to the invention also to improve the wellbeing of animals, for example pets. A
corresponding adjustment of the amounts of active substances used can be made according to the individual species.
The production of a drinking fluid according to the invention can be performed in general so that all inorganic and organic minerals and preferably gases dissolved therein are removed from the drinking water. To this purified clean water the required active ingredients such as vit~mins, proteins, amino acids, minerals and trace elements are added and the resulting obtained product is subjected to a final sterilisation, for example by UV light radiation.
CA 02256l33 l998-l2-l~
Preferably, the concentration of the substances added to the water should reach at most the saturation concentration of the individual components de~ending on the combinations of substances.
To remove dissolved CO2 or to homogenise the thus added active substances, preferably a gaseous medium such as nitrogen or compressed air can be blown through the drinking fluid according to the invention.
For the further activation of the drinking fluid according to the invention it is also possible to change the properties of the product by physical methods, for example by energising, changing the molecular structure or the like.
Of course, for drinking fluids according to the invention it is also possible, preferably after the dissolution of all added substances to add C O2 deliberately, preferably in a concentration above the maximum saturation concentration, so that the end consumer of the drinking fluid can be given a special, bubbly and refreshing taste experience.
ExamDle 1 Drinkinp fluid for oDtimal heart circulation Contents:
vitgm;n~:
CA 022~6133 1998-12-1~
Vitamin C 450 mg/l to 1500 mg/l Vitamin E 2.5 llg/l to 7.5 ~g/l Beta carotene 31.25 llg/l to 100 ~lg/l Vitamin Bl 5 mg/l to 20 mg/l Vitamin B2 5 mg/l to 20 mg/l Vitamin B3 32.5 mg/l to 100 mg/l Vitamin B5 30 mg/l to 100 mg/1 Vitamin B6 7.5 mg/l to 25 mg/l Vitamin Bl2 15 llg/l to 50 llg/l Vitamin D 2.5 llg/l to 7.5 ~lg/l Folic acid 65 ,ug/l to 200 ~g/l Biotin 0.05 mg/l to 0.15 mg/l Minerals:
Calcium 25 mg/l to 75 mg/1 Magnesium 30 mg/l to 100 mg/1 Potassium 15 mg/l to 45 mg/l Phosphorus 10 mg/l to 30 mg/l Trace elements:
Zinc 5 mg/l to 15 mg/1 Manganese 1 mg/l to 3 mg/l Copper 250 mg/l to 1000 mg/l . , CA 022~6133 1998-12-1~
Selenium 15 llg/l to 50 ~g/l Chromium 7.5 ,ug/l to 25 ~g/l Molybdenum 3 ~g/l to 10 ~Lg/l Amino acids and other important cell factors:
Lysine 80 mg/l to 250 mg/l Proline 80 mg/l to 250 mg/l Carnitine 25 mg/l to 75 mg/l Arginine 27.5 mg/l to 82.5 mg/l Cysteine 25 mg/l to 75 mg/l Coenzyme Q- 10 5 mg/l to 15 mg/l Pycnogenol 5 mg/l to 15 mg/l To produce this drinking fluid for supplying the circulation of the heart drinking water can be used as a base, which is purified by suitable methods, e.g.
pressure filtration through a semipermeable membrane or distillation. After sterilisation by e.g. UV light radiation the active ingredients are added, whereby it should be ensured that minerals and trace elements are added in the form of organic salts. In this way for example calcium can be used in the form of lactate, magnesium and potassium as gluconate, manganese and zinc as acetate. Any CO2 still dissolved in the water which has the property on ultra filtration through the filter membrane of diffusing, can be removed by blowing in nitrogen or compressed air for example, and at the said time the added salts CA 022~6133 1998-12-1~
,.._ can be distributed homogeneously. Further positive properties can be given to the product, if the latter for example is energised by means of apparatus functioning according to physical methods or other types of molecular structural changes can be made. For the highest requirements it is also possible to subject the product to a second sterilisation by UV light radiation for example.
The sum of the individual properties of the added vitamins, minerals, trace elements, amino acids and other important cell factors acts positively on the human organism. Thus e.g. vitamin C is vital for the stability of the blood vessels, the heart muscle tissue and other body organs and is also an important wound healing means in our body and responsible for the repair of blood vessel walls. It is the most important antioxidant in our body and an important biocatalyst for many metabolic steps, such as for example the breakdown of cholesterol. In addition, vitamin C is an irreplaceable bioenergy donor of the cell metabolism for the most important energy carrier molecules in ADH, ADP-H and in FAD-H.
Vitamin E (tocopherol) is one of the most important fat soluble antioxidants in the body. It mainly protects the membranes (outer skin) of millions of body cells including the cells of the heart and the artery walls from oxidation damage. In addition, it contributes to the reduced adhesiveness of the blood platelets and advantageous flowing properties of the blood.
I
CA 022~6133 1998-12-1 Beta carotene (provitamin A) is also an additional important fat-soluble antioxidant and contributes to optimum blood viscosity and to a reduced risk of clotting.
Vitamin Bl (thiamine) is a cofactor for pyrophosphate, one of the most important biocatalysts of the metabolism and contributes to the optimum cell energy balance of the heart circulatory system and other organs.
Vitamin B2 (riboflavin) is a structural feature of the FAD energy transport molecule in all cells.
Vitamin B3 (nicotinic acid) is a component of the structure of the energy transport molecule NAD or related energy carriers and thereby partly responsible for supplying energy to the body. By means of the added vitamin C
these used energy carriers are recharged with biological energy. It is particularly important as because of the high work output of the heart muscle cells an optimal supply of these cell fuels is necessary for the heart circulatory system.
Vitamin Bs (pantothenic acid) is a structural component of the acetyl coenzyme -A- molecule, of the central metabolic molecule of each cell of our body. Vitamin Bs is essential in order to prevent backflows in the cell metabolism, as the metabolic paths oi carbohydrates, proteins and fats inside the cells cross one another at this molecule.
- CA 022~6133 1998-12-1~
-Vitamin B6 (pyridoxal phosphate) as a structural component of the pyridoxal phosphate molecule is an important biocalatyst in the metabolism of amino acids and proteins in body cells, essential for the production of red blood cells, which transport oxygen to the cells of the heart circulatory system and other organs.
Vitamin Bl2 (cobalamin) is also necessary for the production of red blood cells. It is also essential for the effective metabolism of proteins and certain fatty acids. A severe Bl2 deficiency results in pernicious anaemia a severe form of anaemia.
Folic acid is also crucial for the transport of oxygen.
The last three vitamins are a good example of the way vitamins work together. It is also important to know which of these natural substances the body needs in what amount.
Biotin is an important biocatalyst for the metabolism of carbohydrates, fats and proteins.
Likewise inositol is a biocatcalyst, responsible for the sugar, fat and protein metabolism. Inositol is also a component of the biological information exchange and assists with the processing of biological information in the cell, . ~ -- CA 022~6133 1998-12-1~
.__ such as e.g. the biological information contained in the hormones. The importance of inositol for the heart circulatory system is quickly evident, as hormones such as adrenaline, insulin and others play an important role in the regulation of the heart function.
As already known from several clinical investigations, the minerals like the vitamins play an important role in the human organism. In particular, the cations are vital components of biocatalysts which are essential in a plurality of metabolic steps. A deficiency or an excess of minerals results in certain cases in life-threatening conditions like a deficiency or an excess of vitamins. Calcium, magnesium and potassium are among the most important minerals.
Calcium has numerous functions in the heart circulatory system. It contributes to muscle contractability and is also responsible for the myocardial transfer. Calcium is important in order to ensure an optimum function of the nerve impulses responsible for a regular heart beat.
Magnesium, the natural calcium antagonist, was able in clinical studies to reduce high blood pressure. It can also contribute to the normalisation of a regular heart beat and plays a role in muscle contraction.
Potassium plays a particularly important role in muscle activity and in nerve transfer. It is also important like calcium to ensure an optimal function of the nerve impulses including the stimulation system of the heart.
, ~ .. . . ..
CA 022~6133 1998-12-1~
. _ Trace elements are essential biocatalysts, which are imperative for a large number of cell metabolic stages. They are only required by the body in very small amounts as already expressed by the term "trace element". A lack of these elements however results in deficiency symptoms. For example with a selenium deficiency cardio myopathy can be observed in Keshan disease.
Amino acids are important building blocks of proteins, which as enzymes of important biocatalysts, as hormones for metabolism regulation or as structural proteins, components of biomembranes or as transport proteins, are responsible for the transport of vital substances, such as e.g. oxygen by haemoglobin. Most amino acids in our body come from proteins which we take in through food. Amino acids which our body can make itself are termed "non essential". Amino acids that the body cannot produce itself and therefore have to be supplied through food are termed "essential" amino acids.
Lysine is an essential amino acid and an important component of collagen and stability molecules. Said amino acid is a significant factor in preventing deposits on the artery wall. In addition, it is a parent substance for the body's own production of earnitine.
Proline is an important building block of collagen molecules and contributes like lysine to the proteetion of the artery wall. Proline can unlike CA 022~6133 1998-12-1 lysine be made by the body itself, the amount of proline produced however is often too low, so that it seem sensible to compensate the requirement by food.
Arginine is the parent substance of vessel wall factors, which leads to a reduced stress of the vessel walls and thereby contributes to a normalisation of high blood pressure. Arginine reduces the adhesiveness of the blood platelets and contributes to an improvement of the flow properties of the blood.
Cysteine is an important parent substance for the production of glutathione an important "body's own" antioxidant. Glutathione together with other antioxidants is responsible for the protection of body tissue from free radicals.
Carnitine can be made in the body itself as a non-essential amino acid.
However, the body's own production is too low as for proline. An optimal supply of carnitine is essential in order to ensure an effective fat metabolism, in particular of triglycerides. In addition, it is an important carrier molecule, which transports fatty acids to extract energy into the biological power houses of the cells (mitochondria). It also ensures the optimal function of the heart muscle cells, which because of their continual work have a high turnover of carnitine. As shown in clinical studies carnitine significantly improves the pumping power of the heart in patients with heart deficiencies. In addition, it is known that carnitine in patients with irregular heart beats (arrhythmia) contributes to a normalisation of the heart rhythm. In both cases carnitine CA 022~6133 1998-12-1 brings about an optimising of the cell energy and thereby an improved performance of millions of heart muscle cells.
Coenzyme Q-10 is also known as ubiquinone and plays an excellent role as a catalyst of the biological respiratory chain in the energy centre of the cells.
It is particularly important for the provision of biological energy in the muscle cells including the heart muscle tissue, which because of the its output has a high turnover of coenzyme Q-10. Here too clinical studies have shown that coenzyme Q-10 in patients with weak hearts can improve the pumping function of the heart.
Pycnogenol comprises a groups of bioflavonoids, which are important as catalysts for various metabolic functions. In particular pycnogenol improves the stabilising effect of vitamin C on the binding tissue of the body including the blood vessel walls and pycnogenol also acts as an antioxidant.
F,x~nple 2 Water for increa~in~ intelli~ence Contents:
Flavonoids 25 mg/l Biotin 50 ~g/l Choline 35 mg/l CA 022~6133 1998-12-1~
._ Folic acid 50 llg/l Inositol 15 mg/l Niacin 25 mg/l Pantothenic acid 25 mg/l Vitamin B6 6 mg/l Vitamin Bl 1.85 mg/l Riboflavin 2.5 mg/l Vitamin A 187.5 mg/l Vitamin Bl2 5 mg/l Vitamin C 50 mg/l Vitamin D 1.5 ~lg/l Vitamin E 0.88 ~lg/l Vitamin K 50 llg/l Calcium 50 mg/l Chromium 0.1 mg/l Magnesium 3.8 mg/l Manganese 0.75 mg/l Molybdenum 0.05 mg/l Iodine 25 llg/l Iron 0. 65 mg/l Zinc 5 mg/l CA 022~6133 1998-12-1~
The production of this drinking fluid can be performed in the same way as the methods described in Example 1.
The advantage of this drinking fluid is that non-verbal intelligence, i.e.
intelligence that is not influenced by schooling or the like can be increased by 10 ~b in a period of up to 8 months. This was proved in an experiment on English school children, who received a combination, which according to German and Austrian guidelines would be available only on prescription and would be inadmissible anyway in its variety. From preliminary investigations it emerged that the children eat a combination of foods (school dinners), which was common practice. If it is taken into consideration that the time period was comparatively short and the organs of children were in very good health, it is understandable why the director of the experiment was surprised by the result.
The conclusion can be drawn from this result that the children against all expectations were malnourished. The suspicion that this is true for the whole population seems justified. The above combination of micronutirents and macronutirents takes into account this fact. With this drinking fluid without additional measures being necessary such as for example the daily intake of tablets or capsules, the intelligence and as a result the productivity of the population can be increased in a simple manner.
F,x~mple 3 -' CA 02256133 1998-12-1~
Water ~in~t the causes of oxidative stress Contents:
Selenium 125 mg/l Vitamin A 125 ~g/l to 250 ,ug/l Vitamin E 12.5 ~g/l to 25 ~g/l Zinc 25 mg/l Vitamin B2 50 mg/l to 100 mg/l Vitamin C 1.5 g/l to 5 g/l Cysteine O.S g/l to 1.5 g/l Vitamin Bl 150 mg/l to 1.5 g/l Vitamin Bs 125 mg/l to 500 mg/l Vitamin B6 125 mg/l to 250 mg/l Choline 0.5 g/l to 1.5 g/l Beta carotene 125 llg/l to 750 llg/l In addition to inadequate nutrition and environmental influences also a large number of medicines increase a radical-forming oxidation process. It has previously not been possible to even halfway copy the immune system of the body, which in normal conditions operates highly effectively. Antibiotics against infections and chemotherapies against cancer never reach the potency of the oxygen. There are and remain substances foreign to the body (xenobiotics) and thus there is an incomplete replacement of natural immunity. They do not CA 022~6133 1998-12-1~
._ differentiate between friend and foe and thus also damage healthy structures.
The doctor thus achieves a main effect at the cost of many side effects.
Medicines can thus worsen the courses of illnesses. The aim of any therapy should be to balance out the redox potential to the value 0. As according to Hypocrates health is the best means against illness a precautionary measure is also to interrupt a possibly already long continuing oxidative stress so that the body can regain its self-regulating abilities. It is possible in many cases, by taking antioxidants or highly dosed nutrients to improve chronic damage, such as e.g. allergies or even remove them altogether. In any case conventional medical therapies should be accompanied to a much greater extent than before by supplements.
In the case of private precautions the emphasis is not on the complete avoidance of illnesses but on a better immunity against unavoidable attacks on health. This is achieved by drinking this water daily.
Example 4 Drinkin~ fluid to cover the daily requirement of vitamins. proteins, amino acids. minerals and trace elements.
Composition:
- -r~
CA 022~6133 1998-12-1 Vitamin A 400 mg/l Vitamin D 2.5 mg/l Vitamin E 5 ~g/l Vitamin C 30 ~g/l Vitamin Bl 0.7 mg/l Vitamin B2 0.8 mg/l Niacin 9 mg/l Vitamin B6 1 mg/l Biotin 75 llg/l Vitamin Bl2 0-5 ~g/l Folacin 100 llg/l Pantothenic acid 3 mg/l Caicium 400 mg/l Phosphorus 400 mg/l Iron 7 mg/l Magnesium 150 mg/l Zinc 7.5 mg/l Iodine 75 )lg/l Effect: Vitamin A supports vision. In addition, the normal structure of the epithelial tissue is dependent on vitamin A. Vitamin A also ensures the stability of the lysosomes and contributes to glycoprotein synthesis. A
. . . . I
CA 022~6133 1998-12-1~
-deficiency causes night blindness, perifollicular hyperkeratosis, xerophthalmy, keratomalacia and increased morbidity and mortality in childhood.
Vitamin E is an intracellular antioxidant and catcher of free radicals in biological membranes. An absence or excess in the body leads to neurological disturbances and zeroid deposits in the muscle.
Vitamin Bl is a coenzyme for the decarboxylation of a-keto acids and the transketolase reaction. A known syndrome with thiamine deficiency is beriberi with peripheral neurological, cerebral and cardiovascular deficiency symptoms. A primary thi~mine deficiency occurs as a result of insufficient intake, especially in the case of exclusive nutrition with machine shelled and polished rice. A secondary thi~mine deficiency occurs with increased need, e.g.
pregnancy, breastfeeding, feverish illnesses and with thyroid hyperactivity with restricted absorption, e.g. prolonged diarrhoea, with restricted utilisation, e.g.
severe liver damage.
Riboflavin (vitamin B2) functions both as a flavin mononucleotide and flavin adenine dinucleotide, as an essential coenzyme in many redox reactions in the carbohydrate metabolism. It is involved in the make up and in the maintenance of mucous membranes. Riboflavin deficiency results in damage to the mouth area, the eyes, the skin and the genital region.
CA 022~6133 1998-12-1~
_ Vitamin C is essential for the formation of collagen and obtains the substances of mesenchymatose origin ~binding tissue, osteoid substance of the bone, dentine of the teeth). It promotes the healing of wounds and the recovery of burns. As a strong reducing agent it can reversibly transfer hydrogen or electrons. Thus it forms in its reduced form, dehydroascorbic acid, a cellular redox system. Vitamin C is involved in the phenylalanine and tyrosine metabolism and activates as a reducing agent the enzymes, which hydroxylise the proline and the lysine of the protocollagen after translation to hydroxyproline and hydroxylysine. Vitamin C also causes folic acid which is coupled with components of nutrients to be released from these conjugations and supports in addition the resorption of iron.
Vitamin B6 is involved in the metabolism of nitrogen e.g. on the transamination of the porphyrine and haem synthesis, the tryptophane conversion to niacin and the linoleic acid metabolism. Deficiencies relate to the metabolism of blood, the skin and the central nervous system.
Vitamin D is important for the resorption of calcium and phosphorus, for the resorption, mineralisation and collagen maturation of bone and for the tubular reresorption of phosphorus. A known bone disease which is caused by vitamin D deficiency is known in children as rickets and in adults as osteomalacia CA 022~6133 1998-12-1~
~ ,._ Vitamin Bl2 contributes to the maturation of red blood cells, neural functions, DNA synthesis in connection with the folic acid coenzymes and to methionine and acetate synthesis.
In addition to the daily supply of corresponding doses of vitamins, as already described above, the daily intake of minerals is particularly important.
For example, calcium and phosphorus are particularly important for the formation of bones and teeth. Phosphorus contributes in addition to energy storage in the form of phosphates, especially adenosine triphosphate, which on consuming energy is reduced to adenosine diphosphate. A deficiency of phosphorus also causes weakness, disruption to the blood cells and irritability.
Iron in turn contributes considerably to the oxygen supply of the human body. It is complexly bonded in haemoglobin, especially in red blood pigment haem and performs the transport of oxygen from the lungs into the cells or removes the products of combustion in particular CO2 from the cells into the lungs. A very low level of iron results in reduced performance or learning difficulties and anaemia.
F,Y~Inple S
Drinkinp fluid for supplyin~ prepn~nt and breastfeedinP mothers Contents:
CA 022~6133 1998-12-1~
Vitamin C 35 mg/l to 47 mg/l Vitamin E S ~g/l to 6 ~Lg/l Vitamin B~ 0.6 mg/l to 0.8 mg/l Zinc 8 mg/l to 9.5 mg/l The adequate nutrition of pregnant or breastfeeding mothers and consequently of the unborn or new born child is of particular importance for maintaining health. A drinking fluid with the above contents can contribute in an advantageous manner to covering the increased need for vit~minc and minerals.
A primary vitamin E deficiency often results in premature babies, in particular if the amount of unsaturated fatty acids in the baby's food is very high. Protein calorie undernourished children often have a low vitamin E serum deficiency. A low vitamin E serum level and haemolysis increased by antioxidation products in premature babies who are fed with foods containing vegetable oil, are found in connection with oedemas and flaky dermatitis. In adults a deficiency in vitamin E results in a reduced lifetime of red blood cells.
Said deficiencies can be avoided by the daily intake of vitamin E.
The effects of vitamin C and vitamin Bl and the effects of a deficiency of these vitamins has already been discussed in the above examples.
. .
CA 022~6133 1998-12-1~
,_ An adequate supply of zinc is particularly important as the zinc content of the body is between 1 g and 2.5 g, whereby the greatest amount is in bones, teeth, hair, skin liver and muscles. The complexing of the zinc supplied with food by means of eating only fibre and phylate rich bread, geophagy and a parasite attack can lead to a reduced resorption and thereby to deficiencies. As known from clinical studies children who have too little zinc in the body show a lack of appetite, are too small and have a reduced sense of taste. A zinc deficiency in the mother can cause anencephaly in children.
Finally, it should be noted that the described drinking fluid with its special combinations of active ingredients are only examples of the solution according to the invention. Individual components of the drinking fluid and different combinations of characteristics to the above examples can form independent solutions according to the invention.
Claims (26)
1. Drinking fluid, comprising water liberated of inorganic and organic mineral substances and preferably degased, characterised in that at least one organic mineral and at least three different vitamins are dissolved therein, whereby zinc is contained as an organic mineral in an amount between 5 mg/l and 25 mg/l, preferably 5 mg/l to 15 mg/l and as vitamins at least vitamin C in an amount 20 µg/l to 5 g/l, preferably 30 µg/l to 5 g/l, vitamin E in an amount from 0.8 µg/l to 27 µg/l, preferably 0.87 µg/l to 25 µg/l and vitamin B1 in an amount 0.6 mg/l to 1.7 g/l, preferably 0.7 mg/l to 1.5 g/l.
2. Drinking fluid according to claim 1, characterised in that it contains vitamin A in an amount between 120 µg/l and 190 mg/l, preferably 125 µg/l to 188 mg/l and/or vitamin B6 in an amount between 0.8 mg/l and 270 mg/l, preferably 1 mg/l to 250 mg/l and/or vitamin B2 in an amount between 0.5 mg/l to 120 mg/l, preferably 0.8 mg/l to 100 mg/l.
3. Drinking fluid according to claim 1 and/or 2, characterised in that as organic minerals it contains calcium in an amount between 5 mg/l and 650 mg/l, preferably 25 mg/l to 400 mg/l and magnesium in an amount between 3.5 mg/l and 250 mg/l, preferably 3.8 mg/l to 150 mg/l and folic acid in an amount between 40 µg/l to 220 µg/l, preferably 50 µg/l to 200 µg/l.
4. Drinking fluid according to one or more of the preceding claims, characterised in that it contains choline in a concentration between 30 µg/1 and 1.8 g/l, preferably 35 µg/l to 1.5 g/l.
5. Drinking fluid according to one or more of the preceding claims, characterised in that as an organic mineral it contains selenium in an amount between 13 µg/l and 250 µg/l, preferably 15 µg/l to 125 µg/l and/or vitamin B5 in an amount between 2.5 mg/l to 0.7 g/l, preferably 3 mg/l to 0.5 g/l and/or beta carotene in an amount from 30 µg/l to 0.90 mg/l, preferably 31 µg/l to 0.75 mg/l and/or cysteine in an amount from 20 mg/l to 1.6 g/l, preferably 25 mg/l to 1.5 g/l.
6. Drinking fluid according to one or more of the preceding claims, characterised in that it contains the vitamin B12 in an amount from 1.3 µg/l to 8 mg/l, preferably 15 µg/l to 5 mg/l and/or D in an amount from 1.3 µg/l to 5 mg/l, preferably 1.5 µg/l to 2.5 mg/l and/or biotin in an amount from 40 µg/l to 0.18 mg/l, preferably 50 µg/l to 0.15 mg/l.
7. Drinking fluid according to one or more of the preceding claims, characterised in that it contains the vitamin B3 in a concentration of between 7 mg/l and 120 mg/l, preferably 9 mg/l to 100 mg/l and/or lysine and/or proline respectively in a concentration of between 70 mg/l to 260 mg/l, preferably 80 mg/l to 250 mg/l.
8. Drinking fluid according to one or more of the preceding claims, characterised in that carnitine is present in a concentration of between 20 mg/l and 280 mg/l, preferably 25 mg/l to 175 mg/l and/or arginine in a concentration of between 25 mg/l and 85 mg/l, preferably 27 mg/l to 82 mg/l and/or coenzyme Q10 in a concentration of between 3 mg/l and 58 mg/l, preferably 5 mg/l to 30 mg/l.
9. Drinking fluid according to one or more of the preceding claims, characterised in that as organic salts it contains potassium and/or sodium in a concentration of 10 mg/l to 70 mg/l respectively, preferably 15 mg/l to 45 mg/l and/or phosphorus, for example as phosphate, in a concentration of between 2 mg/l and 550 mg/l, preferably 3 mg/l to 400 mg/l.
10. Drinking fluid according to one or more of the preceding claims, characterised in that as organic minerals it contains manganese in a concentration of between 0.6 mg/l and 3.4 mg/l, preferably 0.75 mg/l to 3 mg/l and/or chromium in a concentration of between 6 µg/l and 0.12 mg/l, preferably between 7.5 µg/l and 0.1 mg/l and/or molybdenum in concentration of between 2.5 µg /1 and 70 mg/l, preferably 3 µg/l to 5 mg/l.
11. Drinking fluid according to one or more of the preceding claims, characterised in that it contains inositol in a concentration of between 10 mg/l and 80 mg/l, preferably 15 mg/l to 75 mg/l and/or pycogenol in a concentration of between 4 mg/l and 18 mg/l, preferably 5 mg/l to 15 mg/l and/or as an organic mineral copper in a concentration of between 200 mg/l to 1200 mg/l, preferably 250 mg/l to 1000 mg/l.
12. Drinking fluid according to one or more of the preceding claims, characterised in that it contains iron in an amount between 0.5 mg/l to 14 mg/l, preferably 0.65 mg/l to 7 mg/l and/or iodine in an amount between 20 µg/l and 150 µg/l, preferably 25 µg/1 to 75 µg/1.
13. Drinking fluid according to one or more of the preceding claims, characterised in that it contains flavonoids in an amount between 20 mg/l and 40 mg/l, preferably 25 mg/l, and/or vitamin K in an amount between 30 µg/l and 70 µg/l, preferably 50 µg/l.
14. Drinking fluid according to one or more of the preceding claims, characterised in that it contains isoleucine in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 300 mg/l and/or leucine in an amount from 1 mg/l to 1500 mg/l, preferably 11 mg/l to 300 mg/l and/or methionine in an amount from 1 mg/l to 1500 mg/l, preferably 14 mg/l to 300 mg/l.
15. Drinking fluid according to one or more of the preceding claims, characterised in that it contains phenylalanine in an amount from 1 mg/l to 1500 mg/l, preferably 13 mg/l to 300 mg/l and/or threonine in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 200 mg/l and/or tryptophane in an amount from 1 mg/l to 1000 mg/l, preferably 10 mg/l to 200 mg/l and/or valine in an amount from 1 mg/l to 1500 mg/l, preferably 11 mg/l to 300 mg/l.
16. Drinking fluid according to one or more of the preceding claims, characterised in that it contains asparagine in an amount from 1 µg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or serine in an amount from 1 µg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or glutamic acid in an amount from 1 µg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l.
17. Drinking fluid according to one or more of the preceding claims, characterised in that it contains glycine in an amount from 1 µg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or alanine in an amount from 1 µg/1 to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or tyrosine in an amount from 1 µg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l and/or histidine in an amount from 1 µg/l to 10 g/l, preferably 100 mg/l to 1600 mg/l.
18. Drinking fluid according to one or more of the preceding claims, characterised in that as minerals it contains chloride in an amount from 1 mg/l to 100 mg/l, preferably 1 mg/l to 20 mg/l and/or fluoride in an amount from 0.5 µg/l to 1.5 µg/l, preferably 0.5 µg/l to 1 µg/l.
19. Drinking fluid according to one or more of the preceding claims, characterised in that as organic minerals it contains boron in an amount from 0.01 µg/l to 300 µg/l and/or aluminium in an amount from 0.01 µg/l to 50 µg/l.
20. Drinking fluid according to one or more of the preceding claims, characterised in that as organic minerals it contains arsenic in an amount from 0.01 µg/1 to 10 µg/1, preferably 0.01 µg/1 to 2 µg/1 and/or lithium in an amount from 1 µg/1 to 200 mg/l, preferably 1 µg/l to 100 mg/l and/or vanadium in an amount from 1 µg/l to 5 mg/l.
21. Method for producing a drinking fluid, characterised in that all inorganic and organic minerals and preferably any dissolved gases are removed from drinking water, whereupon vitamins and/or proteins and/or amino acids and/or minerals and/or trace elements are added to this pure water according to one or more of the preceding claims, and the thus obtained product is preferably treated to a final sterilisation by e.g. UV light radiation.
22. Method according to claim 21, characterised in that the concentration of the substances added to the water at most reaches the saturation concentration of the individual components depending on the combination of substances.
23. Method according to claim 21 and/or 22, characterised in that to remove dissolved CO2 and for the homogenous distribution of the measured substances preferably nitrogen or compressed air is blown in.
24. Method according to one or more of claims 21 to 23, characterised in the product properties are changed by physical methods, preferably by energising and/or changing the molecular structure.
25. Method according to one or more of claims 21 to 24, characterised in that CO2 is dissolved in the drinking fluid, preferably in a concentration which is above the maximum saturation concentration.
26. Method according to one or more of claims 21 to 25, characterised in that CO2 is added after dissolving all of the added vitamins, amino acids, proteins, minerals and trace elements.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA2130/97 | 1997-12-17 | ||
AT213097 | 1997-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2256133A1 true CA2256133A1 (en) | 1999-06-17 |
Family
ID=3528419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002256133A Abandoned CA2256133A1 (en) | 1997-12-17 | 1998-12-15 | Drinking fluid |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0928565B1 (en) |
AT (1) | ATE249150T1 (en) |
CA (1) | CA2256133A1 (en) |
DE (1) | DE59809565D1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6616955B2 (en) | 2001-01-04 | 2003-09-09 | The Proctor & Gamble Co. | Beverage compositions comprising palatable calcium and magnesium sources |
WO2017060794A1 (en) * | 2015-10-07 | 2017-04-13 | Kauno technologijos universitetas | Method of disinfection of drinking water using ozone and silver cations |
GR20180100482A (en) * | 2018-10-24 | 2020-05-18 | Αλεξανδρος Ηλια Παπαδοπουλος | Orally-administrated aqueous solution of enhanced biological value |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1302863B1 (en) * | 1998-11-13 | 2000-10-10 | Sigma Tau Healthscience Spa | COMPOSITION WITH ANTIOXIDANT AND PREVENTIVE ACTIVITY OF THROMBOTIC AND ATHEROSCLEROTIC ALTERATIONS INCLUDING A CARNITINE AND A |
IL135843A0 (en) * | 2000-04-28 | 2001-05-20 | Ende Michael | Method for production of enhanced traceable and immunising drinking water and other liquids and gases, and devices for use thereof |
NL1019544C2 (en) | 2001-12-12 | 2003-06-13 | Sara Lee De Nv | Device for offering and dispensing mineral water suitable for consumption. |
AU2004242038B2 (en) * | 2003-05-23 | 2010-01-21 | Sara Lee/De N.V. | Assembly of a container filled with mineral concentrate and a dosing device |
NL1023521C2 (en) * | 2003-05-23 | 2004-11-24 | Sara Lee De Nv | Assembly for preparing mineral water, comprises dosing device provided with housing comprising inlet, outlet, liquid flow path, pump, and magnetizable or magnetic operating component manufactured from corrosion resistant steel |
US8893927B2 (en) | 2004-05-24 | 2014-11-25 | Pur Water Purification Products, Inc. | Cartridge for an additive dispensing system |
US8556127B2 (en) | 2004-05-24 | 2013-10-15 | Pur Water Purification Products, Inc. | Additive dispensing system for a refrigerator |
US7767238B2 (en) | 2005-11-04 | 2010-08-03 | Pepsico, Inc. | Beverage composition and method of preventing degradation of vitamins in beverages |
WO2009015669A1 (en) * | 2007-08-02 | 2009-02-05 | Heba-T-Allah Fekry Kamel | Drinking water with vitamins, minerals and amino acids |
AR070594A1 (en) * | 2008-02-08 | 2010-04-21 | Colgate Palmolive Co | DRINK UNDERSTANDING ARGININA |
AT509658B1 (en) * | 2010-04-02 | 2016-01-15 | Dietrichsteiner Christoph Rudolf | PROCESS FOR OPTIMIZING DRINKING WATER |
CN108821401A (en) * | 2018-06-30 | 2018-11-16 | 江苏农牧科技职业学院 | A kind of sewage-treating agent and preparation method thereof for inhaling loach extract containing China |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3201405A1 (en) * | 1982-01-19 | 1983-07-28 | John A. 90024 Los Angeles Calif. Lindon | Mineralised drinking water and process for its production |
WO1995028854A1 (en) * | 1994-04-20 | 1995-11-02 | Duke Marc D | Drink composition for pet animals |
DE69739474D1 (en) * | 1997-04-29 | 2009-08-06 | Procter & Gamble | COLOR-STABILIZED IRON-DRIED MIXTURES, DRINKS AND OTHER FOODS CONTAINED IN IRON, WHICH MAY CONTAIN ZINCES, IF ANY |
-
1998
- 1998-12-08 DE DE59809565T patent/DE59809565D1/en not_active Expired - Lifetime
- 1998-12-08 EP EP98123324A patent/EP0928565B1/en not_active Expired - Lifetime
- 1998-12-08 AT AT98123324T patent/ATE249150T1/en active
- 1998-12-15 CA CA002256133A patent/CA2256133A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6616955B2 (en) | 2001-01-04 | 2003-09-09 | The Proctor & Gamble Co. | Beverage compositions comprising palatable calcium and magnesium sources |
WO2017060794A1 (en) * | 2015-10-07 | 2017-04-13 | Kauno technologijos universitetas | Method of disinfection of drinking water using ozone and silver cations |
US10597315B2 (en) | 2015-10-07 | 2020-03-24 | Kaunas University Of Technology | Method of disinfection of drinking water using ozone and silver cations |
GR20180100482A (en) * | 2018-10-24 | 2020-05-18 | Αλεξανδρος Ηλια Παπαδοπουλος | Orally-administrated aqueous solution of enhanced biological value |
Also Published As
Publication number | Publication date |
---|---|
EP0928565A1 (en) | 1999-07-14 |
DE59809565D1 (en) | 2003-10-16 |
ATE249150T1 (en) | 2003-09-15 |
EP0928565B1 (en) | 2003-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1001685B1 (en) | Nutritional compositions containing methionine | |
CA2256133A1 (en) | Drinking fluid | |
EP2389077B1 (en) | Nutritional supplements for 50+ individuals for improving vitality, immunity, eye and bone health | |
US6562378B1 (en) | Nutritional supplement for adolescents | |
JP2007291135A (en) | Pharmaceutical compositions for alleviating discomfort | |
US20100124587A1 (en) | Creatine-containing vitamin and mineral composition | |
US6565891B1 (en) | Nutritional supplement for children | |
Espinosa-Salas et al. | Nutrition: Micronutrient Intake, Imbalances, and Interventions | |
US20130101569A1 (en) | Hair growth stimulant | |
US20130064924A1 (en) | Nutritional supplement for use under physiologically stressful conditions | |
US20050281888A1 (en) | Nutritional supplement for infants | |
CA2505103A1 (en) | Nutritional supplement for adults | |
Vora et al. | A review on vitamins: it’s biological role and deficiencies in humanS | |
US7998500B2 (en) | Nutritional supplement for women |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |